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Abstract		
Improvements	in	treatment	over	the	past	century	have	greatly	increased	survival	
for	retinoblastoma,	a	rare	childhood	tumour	of	the	eye,	caused	by	mutations	of	the	RB1	
tumour	suppressor	gene.	However,	as	survival	for	retinoblastoma	has	improved,	those	
with	the	hereditary	form	of	the	disease	(RB1	germline	mutation)	have	elevated	risks	of	
developing	additional	cancers,	mostly	bone	and	soft	tissue	sarcomas	and	melanoma.		
Despite	advances	in	understanding	of	second	cancer	risks	following	treatment	for	
retinoblastoma,	key	research	questions	remained	including	1)	risks	of	common	adult-
onset	cancers,	some	of	which	have	somatic	mutations	in	the	RB1	pathway	and	are	
associated	with	ionizing	radiation;	2)	persistence	of	increased	risks	of	bone	and	soft	
tissue	sarcomas	into	adulthood;	3)	clarification	of	risks	of	second	cancers	following	
chemotherapy	to	treat	retinoblastoma	and	4)	role	of	genetic	susceptibility	to	second	
cancers	following	retinoblastoma.	
In	response	to	these	questions,	a	large	cohort	of	1852	long-term	survivors	of	
retinoblastoma	was	assembled	to	evaluate	systematically	the	risk	of	second	cancers.		
The	work	described	in	this	thesis,	which	comprises	six	major	studies,	that	have	used	this	
cohort	to	identify	a	higher	risk	than	previously	assumed	of	lung	cancer;	confirmed	the	
increased	risk	of	second	cancers	in	survivors	with	a	RB1	germline	mutation	and	past	
radiotherapy;	documented	for	the	first	time	that	risk	of	soft	tissue	sarcomas	varied	by	
subtype;	demonstrated	that	mortality	from	second	cancers	exceeded	that	from	
retinoblastoma;	provided	new	information	on	variation	in	second	cancer	risk	by	family	
history	of	retinoblastoma;	and	clarified	that	chemotherapy	in	addition	to	radiotherapy	
for	retinoblastoma	confers	a	higher	risk	for	second	cancers	compared	with	radiotherapy	
alone.		These	studies	collectively	have	provided	risk	data	that	can	be	used	to	inform	
survivors	and	their	health	care	providers	to	facilitate	screening	or	surveillance	and	early	
identification	of	second	cancers.		
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Preface	
The	original	National	Cancer	Institute	study	of	second	cancers	in	retinoblastoma	
survivors	was	started	in	1984	with	the	aim	of	estimating	the	risk	of	second	cancers	in	
relation	to	radiotherapy.	A	study	of	retinoblastoma	patients	treated	in	New	York	had	
estimated	a	90%	risk	of	second	cancers	in	patients	who	had	survived	30	years	after	their	
RB	diagnosis	Abramson	et	al.	(1984).		My	colleagues	at	the	National	Cancer	Institute	
thought	that	this	was	a	higher	than	expected	risk	that	indicated	a	possible	reporting	
bias,	i.e.	those	with	a	second	cancer	were	more	likely	to	respond	to	the	study	than	those	
without	a	second	cancer.		Another	unusual	finding	was	that	the	investigators	did	not	
find	a	relationship	between	increasing	radiation	dose	and	second	cancers.	Therefore,	a	
retrospective	cohort	of	RB	survivors	was	assembled	by	Drs	John	Boice	and	the	late	Fred	
Li	in	collaboration	with	investigators	from	two	well-known	treatment	centres	for	RB		-	
one	in	New	York	City	(included	in	the	previous	study)	and	one	in	Boston,	Massachusetts	
with	the	aim	of	improving	the	completeness	of	follow	up	of	survivors.		Prior	to	my	
undertaking	the	current	set	of	analyses,	two	major	analyses	in	this	cohort	had	been	
conducted	by	my	colleagues.	The	first	analysis	conducted	in	this	cohort	was	a	mortality	
study	of	1601	RB	patients	(Eng	et	al.,	1993)	that	reported	that	patients	with	bilateral	RB	
(RB1	germline	mutation)	had	a	26%	risk	of	dying	of	a	second	cancer	by	age	40	years,	
whereas	those	with	non-hereditary	RB	(RB1	somatic	mutations)	had	only	a	1.5%	chance	
in	the	same	time	period.		Following	on	that	study,	I	collaborated	in	an	incidence	analysis	
(Wong	et	al.,	1997)	of	the	cohort	that	extended	the	follow	up	and	found	a	51%	risk	of	
		
14	
subsequent	incident	cancer	by	age	50	years	in	hereditary	survivors	(RB1	germline	
mutation)	and	a	5%	risk	in	non-hereditary	survivors	(RB1	somatic	mutations).	In	
addition,	we	conducted	a	case-control	study	within	the	cohort	of	soft	tissue	sarcomas	
and	bone	cancers	and	estimated	the	dose	to	the	specific	cancer	site.	A	significant	
positive	radiation	dose-response	for	an	increasing	risk	of	soft	tissue	sarcomas	and	bone	
cancers	with	increasing	dose	of	radiotherapy	for	RB	was	observed	in	these	data.		Many	
of	the	bone	and	soft	tissue	sarcomas	had	been	diagnosed	in	the	head	and	they	were	
clearly	related	to	past	radiotherapy	for	RB	(Wong	et	al.,	1997).	
In	1996,	I	became	the	lead	investigator	at	the	National	Cancer	Institute	for	the	
study	of	second	cancers	in	RB	survivors.	The	two	studies	described	above	by	Eng	et	al	
(Eng	et	al.,	1993)	and	Wong	et	al	(Wong	et	al.,	1997)	formed	the	foundation	for	the	
subsequent	studies	that	I	initiated	and	conducted	in	this	cohort.	As	the	lead	
investigator,	I	continued	to	monitor	the	population	for	risk	of	second	cancers	by	
following	up	the	population	using	a	variety	of	sources	including	commercial	databases	
and	survivor	interviews,	ascertaining	vital	status	and	cause	of	death,	and	initiating	a	
telephone	survey	to	capture	new	information	on	second	cancers,	basic	cancer	risk	
factors	and	current	medical	procedures	and	conditions.	In	addition,	I	expanded	the	
original	cohort	(cohort	1)	to	include	more	recently	treated	patients	with	the	goal	of	
evaluating	the	effect	of	newer	treatments	such	as	chemotherapy	on	the	risk	of	second	
cancers	in	this	population.		For	the	new	cohort	(cohort	2),	I	sought	out	the	necessary	
approvals	and	designed	and	directed	the	data	collection	and	follow-up	including	a	
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telephone	survey	to	ascertain	up	to	date	cancer	information	and	risk	factors.		In	
addition,	I	developed	newsletters	and	a	study	website	(see	Appendix	1)	to	inform	the	
cohort	of	study	findings,	make	recommendations	for	cancer	screening	and	answer	
general	questions	about	the	study	(https://rbstudy.cancer.gov).			
Objective		
Quantify	the	risk	of	second	cancers	in	a	large	cohort	of	long-term	retinoblastoma	
survivors	in	the	United	States.	
Aims	
1)	Systematically	evaluate	the	risk	of	second	cancers	in	a	large	number	of	
survivors	over	a	long	period	of	time	and	quantify	the	risks	of	second	cancers	focusing	on	
genetic	susceptibility	and	treatment.	
2)	Identify	the	risk	of	death	from	second	cancers	in	relation	to	treatment.	
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Chapter	1. Retinoblastoma	–	a	rare	paediatric	ocular	tumour	
1.1 Introduction	
In	this	chapter,	I	am	providing	information	on	the	aetiology	and	treatment	of	
retinoblastoma	and	explain	what	makes	it	a	unique	paediatric	tumour.	I	explain	about	
the	features	that	distinguish	the	two	forms	of	this	cancer,	and	then	go	on	to	describe	
incidence	and	survival	of	this	malignant	ocular	tumour.	Typical	treatments	for	RB	are	
presented.	This	section	is	followed	by	a	discussion	on	second	cancers	in	general	and	
specifically	in	relation	to	treatment	for	a	first	cancer.	Lastly,	I	discuss	some	key	previous	
literature	on	the	risk	of	second	cancers	in	long-term	survivors	of	RB.	
1.2	Aetiology	of	Retinoblastoma	
Retinoblastoma	is	a	rare	paediatric	cancer	of	the	eye	with	an	autosomal	dominant	
inheritance	pattern.	It	is	caused	by	mutations	in	the	RB1	tumour	suppressor	gene,	
located	on	chromosome	13q14	(Weinberg,	2007).		The	RB1	gene	is	one	of	the	most	
commonly	mutated	genes	in	childhood	cancer	(Zhang	et	al.,	2015).	Approximately	80%-
90%	of	RB1	mutation	gene	carriers	develop	ocular	tumours	(Harbour,	2001).	The	RB1	
gene	encodes	the	cell	cycle	regulatory	RB	gene	protein	(pRb),	which	controls	cellular	
differentiation	during	both	embryogenesis	and	in	adult	tissues,	regulates	apoptotic	cell	
death,	maintains	cell	cycle	arrest	and	preserves	chromosome	stability	(Burkhart	and	
Sage,	2008).	When	the	RB1	gene	is	mutated,	it	no	longer	functions	to	suppress	tumours	
and	causes	tumours	of	the	retina	to	form.		
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1.3	Pathogenesis	
Retinoblastoma	is	a	unique	type	of	tumour	because	it	can	occur	in	one	of	two	
forms:		hereditary	(30-40%)	and	non-hereditary	(60-70%).	Hereditary	(or	familial)	RB	is	
caused	by	a	germline	mutation	in	one	allele	of	the	RB1	gene	and	an	acquired	somatic	
mutation	in	the	other	allele,	whereas	the	non-hereditary	form	(or	sporadic)	is	caused	by	
somatic	mutations	in	both	alleles	of	the	gene,	referred	to	as	bilallelic	inactivation	
(Weinberg,	2007)	(see	Figure	1.1).			
The	RB1	germline	mutation	is	either	inherited	from	one	parent	or	the	mutation	
occurs	de	novo	during	formation	of	a	sperm	or	an	egg.		Children	born	to	a	parent	with	RB	
have	a	50%	risk	of	inheriting	the	RB1	mutation.	The	majority	(80-94%)	of	the	de	novo	RB1	
germline	mutations	originate	from	the	father	due	to	multiple	cycles	of	cell	divisions	when	
sperm	are	formed	compared	with	the	relatively	smaller	number	cell	cycle	divisions	
preceding	formation	of	eggs	in	the	mother,	whereas	the	parental	origin	of	somatic	RB1	
mutations	does	not	show	a	paternal	preference	(Weinberg,	2007,	Dryja	et	al.,	1989,	Zhu	
et	al.,	1989).	
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In	contrast	to	the	functional	role	that	the	RB1	gene	plays	in	RB,	the	RB1	gene	is	
somatically	mutated	in	many	adult	cancers	such	as	lung,	bladder	and	colon	(Maris	and	
Knudson,	2015).	Somatic	mutations	in	the	RB1	gene	have	been	reported	in	other	
tumours	such	as	osteosarcomas	and	soft	tissue	sarcoma	(Friend	et	al.,	1987,	Kansara	et	
al.,	2014).	The	loss	of	RB1	function	is	known	to	be	associated	with	both	initiation	and	
Figure	1.1.	Mutations	in	bilateral	and	unilateral	retinoblastoma	
(Weinberg	R,	Cancer	2006).	In	the	familial	form,	a	germline	mutation	in	
the	RB1	gene	is	inherited	and	a	somatic	mutation	occurring	at	random	is	
required	for	the	disease	to	appear	in	the	retina	in	both	eyes,	whereas	in	
the	sporadic	form	of	retinoblastoma,	two	somatic	mutations	occur	at	
random	in	the	gene	and	cause	the	cancer	in	one	eye.	
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progression	of	more	common	adult	cancers	via	several	hypothesised	mechanisms	
(Burkhart	and	Sage,	2008).	The	frequency	of	RB1	inactivation	varies	by	cancer	type.		
Somatic	RB1	mutations	have	been	identified	in	the	pathway	of	small	cell	lung	cancer	
(Harbour	et	al.,	1988)	and	the	RB1	gene	is	inactivated	in	90%	of	these	cancers.	RB1	
inactivation	is	also	considered	an	initiating	event	in	some	familial	cases	of	melanoma	
(Shennan	et	al.,	2000).		Progression	of	prostate,	breast,	bladder,	brain,	oesophageal,	
ovarian	and	liver	cancer	as	well	as	chronic	myeloid	leukaemia	have	also	been	attributed	
to	inactivation	of	the	RB1	gene	(Burkhart	and	Sage,	2008,	Sharma	et	al.,	2010,	Song	et	al.,	
2006).	
1.4	Clinical	Features	
The	affected	eye	or	eyes	with	RB	most	commonly	presents	with	leukocoria	
(“white	pupil”)	(about	54%)	and	less	commonly	with	strabismus	(cross-eyes)	
(19%)(Abramson	et	al.,	2003).	RB	is	sometimes	diagnosed	as	a	result	of	an	incidental	
finding	of	an	abnormal	red	reflex	following	flash	photography	in	children	(Damasco	and	
Dire,	2011).		
	
	
	
		
	
Figure	1.2	Eye	with	retinoblastoma	presenting	with	leukocoria	(Weinberg,	2007).		
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The	hereditary	form	of	RB	is	characterized	clinically	by	disease	in	both	eyes	
(bilateral	RB)	and	is	typically	diagnosed	before	12	months	of	age,	whereas,	the	non-
hereditary	form	affects	one	eye	(unilateral	RB)	and	is	typically	diagnosed	between	2-5	
years	of	age.		
These	differences	in	age	at	diagnosis	of	bilateral	and	unilateral	RB	led	Knudson	to	
develop	the	two-hit	theory	(Knudson,	1971),	in	which	only	one	additional	somatic	
mutation	or	hit	is	needed	for	hereditary	RB,	hence	the	younger	age	at	diagnosis.	
However,	two	somatic	mutations	(hits)	are	required	for	non-hereditary	RB,	hence	the	
older	age	at	diagnosis,	because	it	takes	longer	to	acquire	the	two	mutations.		
	
Figure	1.3.	Graph	shows	earlier	age	at	diagnosis	of	bilateral	retinoblastoma	
cases	compared	with	unilateral	cases	(Weinberg,	2007).		
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About	10-15%	of	patients	with	unilateral	RB	carry	a	germline	RB1	mutation	and	
have	a	family	history	of	RB.	These	RB1	germline	mutations	are	considered	to	be	a	less	
penetrant	form	of	RB	because	only	one	eye	rather	than	both	have	tumours.	This	type	of	
mutation	is	sometimes	referred	to	as	mosaicism,	because	only	some	but	not	all	of	the	
germline	genes	are	mutated.	The	proportion	of	unilateral	patients	with	mutations	that	
were	mosaic	was	estimated	to	be	3.8%	(Rushlow	et	al.,	2009)	but		recent	studies	have	
indicated	that	up	to	10%	of	unilateral		patients	have	a	RB1	germline	mutation	that	was	
mosaic	(Amitrano	et	al.,	2015,	Dommering	et	al.,	2014).		
Table	1.1	Features	distinguishing	hereditary	and	non-hereditary	retinoblastoma	
Feature	 Hereditary	(familial)	 Non-hereditary	(sporadic)	
Type	of	RB1	mutation	 Germline	+	somatic	 Somatic	only	
Inherited	mutation	 Inherited	(15%)	or	de	novo	
(85%)	
No	
Typical	age	at	diagnosis	 <1	year	 2-5	years	
Number	of	eyes	with	
disease	
Both	eyes	or	one	eye	with	
family	history	of	RB	
One	eye	only	*	
Family	history	of	RB	 Yes	 No	
Proportion	in	general	
population	
40%	 60%	
Mosaicism	 8.8%	 1.2	-10%	
1.5	Incidence	and	Survival		
The	age-adjusted	annual	incidence	rate	of	retinoblastoma	from	2008-2012	in	the	
US	for	both	sexes	and	all	races	for	ages	0-19	years	is	3.2	per	10
7
,	with	a	small	but	
significant	decline	of	0.4	per	cent
	
in	incidence	over	the	past	37	years	(Howlader,	2016).	
Retinoblastoma	is	the	most	common	childhood	cancer	under	age	4	for	both	boys	and	
girls.	Among	children	under	one	year	of	age,	the	incidence	was	29.2	per	10
7	
children	and	
among	ages	1-4,	the	incidence	is	8.7	per	10
7			
children.			The	5-year	relative	survival	for	
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the	most	recent	time	period	(2005-2011)	is	97.5%	in	the	U.S.	and	did	not	differ	by	sex	
(Howlader,	2016).		RB	is	diagnosed	in	one	in	20,000	births,	and	approximately	300	new	
cases	are	diagnosed	each	year	in	the	United	States	(Wong	et	al.,	2014).		In	lower	income	
countries,	RB	tends	to	be	diagnosed	at	later	stages	that	negatively	affect	survival,	and	is	
more	likely	to	be	non-hereditary	that	Stiller	and	Parkin	suggest	could	be	related	to	poor	
living	conditions	and	a	possible	infectious	aetiology	(Stiller	and	Parkin,	1996).		
1.6	Treatment	of	Retinoblastoma	
In	high-income	countries,	patients	with	RB	are	usually	treated	at	specialist	centres	
by	ocular	oncologists	or	ophthalmologists.	Treatment	for	RB	historically	has	consisted	
primarily	of	radiotherapy	(both	external	beam	and/or	radioactive	plaques),	enucleation	
(removal	of	the	eye),	chemotherapy,	focal	therapies	such	as	laser	or	cryotherapy,	or	a	
combination	of	these	modalities	depending	upon	the	extent	of	the	cancer,	laterality	and	
the	ability	to	preserve	vision	(Rodriguez-Galindo	et	al.,	2015).		For	children	with	unilateral	
RB,	the	eye	is	often	removed	(enucleation)	and	no	further	treatment	is	needed.	These	
children	are	fitted	with	a	prosthetic	eye	that	is	periodically	replaced	as	the	child	grows	
older.	However,	for	children	with	bilateral	RB,	one	eye	is	often	removed	and	the	other	
eye	is	treated	with	radiation	(either	fractionated	external	beam	radiation	or	radioactive	
plaque	depending	upon	the	location	and	size	of	the	tumour)	to	preserve	sight	in	the	less	
diseased	eye.		The	location	of	the	tumour	within	the	eye	determines	the	likelihood	that	
external	beam	radiation	will	be	successful.		In	addition,	depending	upon	the	stage	of	the	
RB,	both	eyes	may	be	treated	with	radiation	or	both	eyes	may	be	removed.	Although	
external	beam	radiation	may	preserve	sight	in	the	eye,	there	is	often	cosmetic	facial	
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deformity	of	the	orbital	bones	by	the	radiation	because	orbital	growth	that	is	in	progress	
during	early	childhood	is	disrupted	(Rodriguez-Galindo	et	al.,	2015).	
Systemic	chemotherapy	has	been	used	since	1950	to	treat	RB	mainly	in	
combination	with	radiotherapy;	treatment	patterns	shifted	in	the	1990s	with	less	use	of	
radiotherapy	to	greater	use	of	chemotherapy	to	treat	RB.		Recent	trends	in	the	US	
indicate	a	significant	decline	in	use	of	radiotherapy	to	treat	RB	from	30.5%	in	the	1980s	
to	2.6%	after	1999	pointing	to	the	increased	use	of	chemotherapy	(Shinohara	et	al.,	
2014).	
	
Figure	1.4.	Radiotherapy	trends	by	calendar	year	by	laterality	(Shinohara	et	al.,	
2014)		
In	the	last	decade,	there	has	been	a	significant	shift	to	the	use	of	ophthalmic	
artery	chemosurgery	(local	administration	of	chemotherapy	to	the	ophthalmic	artery)	
and	intravitreous	chemotherapy	(Gobin	et	al.,	2011)	(Abramson	et	al.,	2015b),	in	order	to	
spare	children	exposure	to	systemic	chemotherapy,	which	has	been	linked	to	the	
development	of	acute	myeloid	leukaemia	in	RB	survivors	(Gombos	et	al.,	2007).	This	new	
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method	continues	to	be	refined	and	used	to	treat	advanced	unilateral	and	bilateral	RB	
patients	(Abramson	et	al.,	2015a,	Abramson	et	al.,	2015b).		
Table	1.2	Retinoblastoma	treatments	by	laterality	and	decade	in	the	US	cohort	
Years	of	
Treatment	
Bilateral	–	typical	treatments	 Unilateral	–	typical	
treatments	
1914-1949	 Enucleation	in	one	eye	and	radiation	
(fractionated	external	beam	or	
brachytherapy)	in	other		
Radiation		in	both	eyes	
Enucleation	in	both	eyes	
Enucleation		
Radiation	
1950s-1960s	 Enucleation	in	one	eye,	radiation	in	
other	eye	and	systemic	
chemotherapy	
(Triethylenemelamine)	
Enucleation	
Radiation	
1970s-1990	 Enucleation	in	one	eye,	radiation	in	
one	eye	and	systemic	chemotherapy	
Focal	therapies:	e.g.	laser,	
cryotherapy		
Enucleation		
Chemotherapy	
1990s-	 Focal	therapies:	laser	
photocoagulation,	cryotherapy	and	
brachytherapy	
	Enucleation	and	systemic	
chemotherapy	
External	beam	radiation	when	other	
treatments	have	failed.		
Enucleation	
Chemotherapy	
2000-2006	 Chemotherapy	(intra-arterial,	
intravitreal	or	systemic)	
Chemotherapy	(systemic	or	
intra-arterial	or	intravitreal)	
and	focal	therapies	
	
1.7	Second	cancers		
Second	cancers	have	become	an	important	concern	for	childhood	cancer	
survivors	due	to	major	improvements	in	treatment	and	increased	survival	of	the	first	
cancer	(Reulen	et	al.,	2011,	Morton	et	al.,	2014b).		Second	cancers	represent	17-19%	of	
all	new	cancers	in	children	and	adults	(Morton	et	al.,	2014b).		In	order	to	study	second	
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cancers	in	paediatric	cancer	populations,	large	numbers	of	patients	are	needed,	because	
childhood	cancers	are	rare	and	many	years	of	follow	up	are	required	to	study	increased	
risks	with	sufficient	statistical	power	(Morton	et	al.,	2014b).		
Second	cancers	are	histologically	different	malignant	tumours	that	develop	in	
patients	with	a	first	cancer.	Second	cancers	can	be	diagnosed	at	the	same	time	as	the	
first	cancer	(synchronous	cancer)	or	at	later	time	(metachronous	tumours).	Treatment,	
genetic	predisposition,	host,	medical,	lifestyle	and	environmental	factors	such	as	tobacco	
can	all	contribute	to	the	risk	of	second	cancers.		However,	the	most	important	factors	
that	account	for	the	risk	of	second	cancer	in	children	and	young	adults	are	treatment	for	
the	first	cancer	and	genetic	susceptibility	(Morton	et	al.,	2014b).	
Both	radiotherapy	and	chemotherapy	have	been	linked	to	increased	risks	of	
second	cancers	in	children	and	adults	(Morton	et	al.,	2014a).		Multiple	studies	of	
paediatric	and	adult	cancer	survivors	have	reported	that	second	solid	cancers	typically	
develop	10-15	years	after	radiotherapy	(Friedman	et	al.,	2010,	Ng	and	Travis,	2008).	
Patients	are	exposed	to	multiple	sources	of	scatter	radiation	during	treatment	from	the	
external	beam	itself,	the	collimator	head	as	well	as	scatter	throughout	the	body.	
Chemotherapy	for	treatment	of	a	first	cancer,	in	particular	alkylating	agents	or	
epidophyllotoxins	are	known	to	cause	DNA	damage	that	can	lead	to	diagnosis	of	an	acute	
myeloid	leukaemia	as	early	as	18	months	after	the	first	cancer	(Morton	et	al.,	2014a).		
Recently,	studies	of	childhood	cancer	survivors	have	reported	increased	risks	of	selected	
second	solid	tumours	related	to	chemotherapy	for	a	first	cancer	(Henderson	et	al.,	2015,	
Swerdlow	et	al.,	2011).	
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Genetic	susceptibility	or	inherited	cancer	syndromes,	such	as	retinoblastoma,	Li	
Fraumeni,	neurofibromatosis	1	(NF-1)	and	Nevoid	Basal	Cell	Cancer	(NBCCS)	syndromes	
increase	risk	of	specific	cancers	due	to	the	presence	of	germline	mutations,	and	exposure	
to	radiotherapy	may	increase	the	risk	of	additional	cancers	(Kleinerman,	2009,	Zhang	et	
al.,	2015).	For	example,	children	and	adults	with	Li-Fraumeni	syndrome	are	at	increased	
risks	of	sarcoma,	breast	cancer	and	adrenocortical	cancers	due	to	a	germline	p53	
mutation.		Radiotherapy	to	treat	these	cancers	has	been	reported	to	be	related	to	the	
risk	of	another	cancer	(Hisada	et	al.,	1998).		
Environmental	factors	such	as	sun	exposure	(ultraviolet	radiation)	or	lifestyle	
factors	such	as	smoking	tobacco	can	increase	the	risk	of	second	cancers	either	
independently	or	through	an	interaction	with	other	factors,	although	these	factors	are	
more	of	an	issue	for	adult	than	paediatric	patients	(Morton	et	al.,	2014b).		
1.8	Second	cancers	after	retinoblastoma:		Literature	review			
Second	cancers	have	been	recognized	as	a	risk	among	hereditary	retinoblastoma	
survivors	in	numerous	case	reports,	several	clinical	series	and	in	two	population-based	
cohorts	in	the	UK	(MacCarthy	et	al.,	2013)	and	the	Netherlands	(Marees	et	al.,	2008b).		
These	two	population-based	cohorts	are	the	most	relevant	to	the	US	cohort	in	size,	
length	of	follow-up	and	risk	estimates	for	second	cancers	(Table	1.3).				
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Table	1.3.	Risk	of	second	cancers	in	cohort	studies	of	long-term	survivors	of	
retinoblastoma	
	 	 Hereditary	 Non-hereditary	
Cohort		
Diagnosis	
years	
No.	of	
patients	
No.	2nd	
cancers	 SIR
1
	
No.	of	
patients	
No.	2nd	
cancers	 SIR
1
	
USA	
(n=1601)
2
,	
3	
	
1914-
1984	
963	 260	
19	
(16-21)	
638	 17	
1.2	
(0.7-2.0)	
UK
	
(N=1927)
4
		
	
1951-
2004	
806	 112	
14	
(11-16)	
1121	 20	
1.5		
(0.9-2.3)	
Netherlands	
(n=608)
5
		
	
1945-
2005	
298	 62	
20	
(16-26)	
370	 12	
1.9	
(1.0-3.2)	
	 	 	 	 	 	 	
1
SIR,	Standardised	incidence	ratio	and	95%	confidence	interval.	This	is	the	number	of	
observed	cancers	divided	by	the	number	of	cancers	expected	from	the	general	
population.	
2	
Number	in	parentheses	is	the	total	number	of	subjects	in	the	cohort.	
3		
(Kleinerman	et	al.,	2005)	1-year	survivors,	hospital-based	
4
	(MacCarthy	et	al.,	2013)	3-year	survivors,	population-based	
5
	(Marees	et	al.,	2008a)	all	survivors,	register-based
	
	
Initially	the	UK	cohort	was	comprised	of	884	children	diagnosed	with	RB	from	
1962-77.		Draper	et	al	(Draper	et	al.,	1986)	reported	a	cumulative	risk	of	8.4%	for	all	
second	cancers	after	18	years	and	6.0%	for	osteosarcoma	among	the	384	hereditary	RB	
survivors.	Within	the	field	of	radiation,	the	cumulative	risk	was	6.6%	for	all	second	
cancers.		This	study	also	suggested	relationships	between	cyclophosphamide	and	second	
cancers	and	melanoma	in	hereditary	RB	survivors.		Subsequent	study	by	Hawkins	et	al	
(Hawkins	et	al.,	1987)	in	363	three-year	hereditary	survivors	reported	cumulative	risks	of	
second	cancers	at	15	years	after	treatment	were	2.7%	for	surgery	only,	6.8%	for	
radiotherapy	alone	and	13%	for	radiotherapy	and	chemotherapy.	Further	modelling	of	
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the	risk	of	osteosarcomas	in	relation	to	chemotherapy	and	radiotherapy	in	this	
population	indicated	a	positive	dose-response	for	increasing	risk	with	increasing	dose	of	
both	types	of	treatment	(Hawkins	et	al.,	1996).	MacCarthy	et	al	have	recently	reported	
increased	risks	of	second	cancers	similar	to	those	noted	in	our	cohort	(MacCarthy	et	al.,	
2013).		Although	that		study	did	not	report	treatment	data,	it	did	report	risks	within	the	
head	and	neck	region	and	outside	the	region,	which	served	as	a	surrogate	variable	for	
radiation	to	the	head.		
DerKinderen	studied	141	children	diagnosed	with	hereditary	RB	from	1945-1970	
in	the	Dutch	Retinoblastoma	Registry	and	reported	a	cumulative	risk	of	second	cancers	of	
19%	at	35	years	(Derkinderen	et	al.,	1987).		Moll	et	al	(Moll	et	al.,	1996)	updated	the	
Register	to	1994	and	reported	a	cumulative	incidence	of	17.7%	for	second	cancers	in	639	
hereditary	survivors.		This	cohort	has	been	expanded	to	include	more	recently	treated	
patients	and	continues	to	be	followed	for	risk	of	second	cancers	in	relationship	to	
treatment	(Marees	et	al.,	2008b,	Marees	et	al.,	2010).		Their	findings	are	very	similar	to	
the	US	cohort	in	terms	of	relative	risk	estimates	for	all	second	cancers	in	relation	to	
radiotherapy.	The	UK	and	Dutch	cohorts	however	excluded	pineoblastomas	as	
independent	second	cancers	in	their	studies,	whereas	we	have	included	them	in	the	US	
studies,	because	they	all	occurred	at	least	one	year	after	RB	diagnosis.			
The	earlier	studies	of	second	cancers	after	RB	from	the	Netherlands	(Derkinderen	
et	al.,	1987)	(Moll	et	al.,	1996)	and	the	UK	(Draper	et	al.,	1986)	(Hawkins	et	al.,	1996)	
preceded	development	of	the	US	cohort	of	RB	patients.		However,	several	of	the	follow-
up	studies	of	these	same	cohorts	were	published	either	after	or	contemporaneously	with	
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the	publication	of	the	initial	US	studies	(Fletcher	et	al.,	2004,	Marees	et	al.,	2008b,	
MacCarthy	et	al.,	2013).	The	next	chapter	presents	the	development	and	details	of	the	
US	cohort	of	RB	patients.	
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Chapter	2. Description	of	the	National	Cancer	Institute	retinoblastoma	
cohort				
2.1	Introduction	
This	chapter	describes	the	source	of	study	population	that	comprises	the	US	
cohort,	methods	of	data	collection,	ascertainment	of	second	cancer	incidence	and	
mortality	as	well	as	treatment.		The	statistical	methods	used	in	the	analyses	that	are	
presented	in	the	subsequent	chapters	are	described	in	this	chapter.		
2.2	Overview	of	the	cohort	
The	National	Cancer	Institute	(NCI)	retinoblastoma	study	is	a	multi-institutional,	
hospital-based	retrospective	cohort	design	with	long-term	follow	up	of	subsequent	
cancer	incidence	and	mortality.		
RB	patients	were	originally	identified	from	medical	records	at	two	medical	
centres:		in	New	York	and	in	Boston.		These	two	medical	centres	were	selected	because	
they	are	major	treatment	centres	for	RB	and	the	clinical	investigators	at	these	sites	
wanted	to	collaborate	in	the	research.	Study	subjects	were	identified	solely	through	
medical	records	at	these	two	treatment	centres	and	the	subjects	were	treated	between	
1914-1984	(cohort	1)	and	1985-1996	(cohort	2).		
The	Special	Studies	Institutional	Review	Board	(SSIRB)	of	the	NCI	as	well	as	the	
Institutional	Review	Boards	(IRBs)	of	the	participating	medical	centres	approved	the	
study.	Continuing	annual	IRB	review	of	the	study	and	approval	is	obtained	from	the	NCI.	
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2.3	Study	population	
Eligible	study	subjects	had	to	have	been	diagnosed	with	either	unilateral	(one	eye	
affected)	or	bilateral	(both	eyes	affected)	RB	as	determined	by	diagnoses	recorded	in	
medical	records.	All	bilateral	patients	were	classified	as	hereditary	as	well	as	unilateral	
patients	with	a	documented	history	in	the	medical	record	of	RB	in	a	first	or	second	
degree	relative,	excluding	having	a	child	with	RB.	All	other	unilateral	patients	were	
classified	as	non-hereditary.	There	were	no	age	restrictions	on	eligibility.	All	patients	had	
to	be	US	residents	so	they	could	be	followed	with	available	US	databases	(e.g.,	the	US	
National	Death	Index,	NDI)	and	they	had	to	survive	at	least	one	year	after	their	RB	
diagnosis.	This	restriction	was	included	in	order	to	assure	that	the	subsequent	cancer	
was	diagnosed	at	least	one	year	after	the	RB	and	was	not	a	synchronous	tumour	nor	
likely	to	be	associated	with	intense	medical	surveillance	during	the	first	year	after	RB	
diagnosis.		
Cohort	1:		The	original	cohort	(Cohort	1)	was	the	larger	of	the	two	cohorts	and	
included	RB	patients	treated	in	New	York	or	Boston	from	1914-1984.	Medical	records	
were	found	for	a	total	of	1,729	RB	patients	who	were	treated	during	this	time	period.		
We	excluded	114	(6.4%)	patients	who	died	within	12	months	of	diagnosis	of	RB,	11	
(0.6%)	who	died	outside	the	US,	2	(0.1%)	patients	with	an	unknown	birth	year,	1	(0.1%)	
patient	who	was	determined	not	to	have	RB,	which	left	1,601	(92.7%)	one-year	survivors	
of	RB	eligible	for	study.			
Cohort	2:	I	expanded	the	original	cohort	to	develop	cohort	2	in	order	to	capture	
information	on	patients	who	were	treated	more	recently	and	therefore	were	more	likely	
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to	have	been	treated	with	newer	treatments	such	as	chemotherapy.	Medical	records	
were	identified	for	262	RB	patients,	however	we	excluded	7	patients	(2	died	within	1	
year,	2	were	seen	for	consultation	only	and	2	were	lost	to	follow-up	(no	usable	tracing	
information).	After	these	exclusions,	cohort	2	is	comprised	of	253	RB	patients	treated	
from	1985-1996	at	one	medical	centre	in	New	York.	I	selected	the	New	York	centre	due	
to	the	large	volume	of	RB	patients	treated	annually	at	that	institution.		
The	proportion	of	hereditary	(60%)	and	non-hereditary	(40%)	RB	patients	in	the	
study	(cohorts	1	and	2)	differs	from	the	proportion	in	the	US	general	population	in	which	
only	40%	have	hereditary	disease	and	60%	have	non-hereditary	disease.	This	is	likely	due	
to	the	source	of	the	RB	patients	from	major	medical	centres	specialising	in	the	treatment	
of	RB.	Because	RB	is	a	rare	disease	as	are	second	cancers,	the	advantage	of	having	more	
hereditary	patients	in	the	cohort	allowed	a	larger	pool	of	patients	who	were	more	prone	
to	developing	second	cancers,	and	thus	we	were	able	to	conduct	more	detailed	analysis	
of	second	cancers.			
2.3	Data	collection	
Data	collection	efforts	consisted	of	two	phases	and	were	similar	in	both	cohorts	--	
1)	medical	record	abstraction	to	establish	baseline	data	on	diagnosis	and	treatment,	and	
2)	Follow	up	via	interview	and	electronic	data	linkages	to	determine	vital	status	and	
identify	second	cancers.		
Using	a	standardised	medical	record	abstract	form	(Appendix	A1),	trained	medical	
record	abstractors	recorded	baseline	diagnosis	and	treatment	information	from	hospital	
records	including	dates	of	diagnosis	and	treatment,	laterality,	mention	of	family	history	
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of	RB,	type	of	treatment	(radiotherapy	–	external	beam,	radioactive	plaque	or	both),	
chemotherapy	(name	of	drug),	surgical	procedures	–	type	specified	including	removal	of	
eye	or	enucleation)	as	well	as	any	mention	of	a	subsequent	cancer	or	death.		
For	cohort	2,	we	initially	reviewed	the	roster	of	RB	patients	manually	to	identify	
patients.	Because	patients	made	multiple	visits	to	the	hospital	ocular	oncology	clinic,	we	
needed	to	be	sure	that	we	were	only	counting	each	patient	one	time	to	develop	the	
cohort.	Next	we	abstracted	data	from	medical	records	for	these	patients	using	the	same	
medical	record	abstract	form	as	cohort	1	and	recorded	contact	information	so	that	we	
could	contact	either	the	survivors	or	their	parents,	if	under	age	18,	to	gain	additional	
information	about	subsequent	cancers.	We	contacted	this	same	group	by	telephone	in	
1998	and	2009	to	update	their	subsequent	cancer	information.	(Figure	2.1)	
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RB	Cohort	1	
(1925-1984)	medical	records	abstracted	=	1729	
	
Exclusions	(n=128)	
No	RB,	n=1	
Died	<1	year	after	RB	n=114	
Died	outside	US,	n=11	
Unknown	date	of	birth	n=2	
N=1601	1-yr	
survivors	
RB	Cohort	2	
	(1985-1996)	medical	records	abstracted	N=262	
	
Lost	to	follow	up,	n=2	
	
N=1599	1-yr	
survivors	
N=255	1-yr	
survivors	
N=253	1-yr	survivors	
Exclusions	(n=7)	
Died	<1	yr,	n=2	
								Consultation	only,	n=2	
Missing	RB	date,		n=3	
Lost	to	follow	up,	n=2	
	
RB	Cohorts	1	&	2	Combined:	N=1852	1-yr	survivors	
Figure	2.1	Description	of	Cohort	
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2.4	Vital	status	and	death	ascertainment	and	follow	up	procedures	
The	lack	of	available	personal	identification	numbers	and	a	national	cancer	
registry	in	the	US	makes	locating	study	subjects,	updating	vital	status	and	obtaining	
second	cancer	information	very	challenging.		As	a	result,	we	used	a	variety	of	sources	to	
ascertain	vital	status	and	current	address	that	included	post	office	correction	updates,	
commercial	credit	bureau	linkages,	social	security	administration	linkage,	individual	
tracing	through	publicly	available	sources	and	linkage	with	the	NDI.		
The	Social	Security	Administration	(SSA)	is	responsible	for	paying	survivor	death	
benefits	to	US	citizens.	They	maintain	mortality	files	as	well	as	a	‘presumed	living’	file	for	
people	with	a	social	security	number	who	have	not	collected	death	benefits.	We	linked	
our	study	subjects	with	a	social	security	number	(about	90%)	with	the	SSA	to	ascertain	
current	vital	status.	Ascertainment	of	death	from	the	Social	Security	Death	Master	File	
relied	on	submitting	a	correct	having	a	social	security	National	Death	Index	depended	
upon	having	good	matching	information	for	linkage.		
The	NDI	provides	information	on	deaths	for	87%-98%	of	the	US	population	
(Cowper	et	al.,	2002).	Individual	states	have	to	report	date	and	cause	of	death	to	the	NDI.		
Cause	of	death	has	been	available	since	1979	and	coded	cause	of	death	since	1984.		
There	is	a	two-year	lag	in	reporting	deaths	by	the	NDI.		The	NDI	uses	a	matching	
algorithm	to	determine	matches,	and	the	best	matches	are	those	that	are	an	exact	match	
on	date	of	birth	and	social	security	number.	If	a	social	security	number	is	missing	or	the	
subject	has	a	common	name,	then	the	match	would	be	less	certain.		When	the	NDI	
reports	death	matches,	we	review	the	matches	and	in	some	cases	we	may	reject	the	
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match	if	we	think	it	is	not	the	same	person	because	of	a	difference	in	place	of	birth,	for	
example.	Over	the	lifetime	of	the	cohort,	we	have	been	linking	the	cohort	with	the	NDI	
usually	every	2-3	years	rather	than	every	year	due	to	the	cost	involved	in	the	linkage.	We	
estimate	that	we	may	be	missing	up	to	5%	of	the	deaths	in	this	study,	based	on	reports	
from	relatives	for	deaths	that	we	missed	because	the	subject	either	died	out	of	country	
or	was	missed	by	the	NDI.		
For	deaths	prior	to	the	establishment	of	the	NDI,	we	had	requested	death	
certificates	from	the	individual	state	where	a	patient	died,	unless	the	death	certificate	
was	available	in	the	medical	record.	In	addition,	using	multiple	vital	status	tracing	
methods	has	been	reported	to	enhance	mortality	follow-up	in	large	cohort	studies	(Schall	
et	al.,	2001).	
In	order	to	collect	cancer	incidence	data,	we	conducted	multiple	telephone	
interviews	in	1987,	1993,	1996,	2000	and	2009	to	ascertain	current	health,	subsequent	
tumours	(benign	and	malignant)	and	basic	cancer	risk	factor	data	(2000	telephone	survey	
only).		
2.5	Ascertainment	of	second	cancers	
All	subsequent	invasive	cancers	were	ascertained	from	medical	records,	physician	
notes,	autopsy	reports,	interviews	with	subjects	or	their	parents,	and	the	NDI.	There	is	no	
national	cancer	registry	in	the	US.	There	are	individual	state	cancer	registries	but	they	
vary	in	quality	and	years	of	coverage.	Given	the	lack	of	a	national	cancer	registry	in	the	
United	States,	we	were	primarily	dependent	on	contact	with	survivors	to	obtain	incident	
cancers.		If	we	were	able	to	contact	a	survivor	then	we	had	current	information.	But	if	we	
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were	unable	to	contact	a	survivor	whom	we	knew	was	alive	and/or	they	refused	to	
participate,	then	we	had	no	information	on	their	second	cancers,	unless	there	was	
already	documentation	of	a	second	cancer	in	the	medical	record	from	when	we	
abstracted	medical	records	at	the	beginning	of	the	study	in	1984.	The	majority	of	the	
cohort	had	been	treated	for	RB	in	the	1960s,	and	we	did	identify	80	confirmed	second	
cancers	at	the	time	of	the	medical	record	abstraction.	If	subject	had	died	prior	to	1984	or	
since	that	time	and	we	were	never	able	to	contact	them	to	ask	about	second	cancers,	
then	we	relied	on	what	we	found	in	their	medical	record	at	the	time	of	start	of	the	study	
in	1984	and/or	at	their	cause	of	death	if	it	was	a	cancer.	
Because	many	of	the	subsequent	tumour	reports	were	self-reports,	we	
attempted	to	confirm	these	by	obtaining	pathology	reports	from	the	hospital	where	the	
cancer	was	diagnosed.	Persons	trained	to	code	cancers	coded	all	pathology	reports	
according	to	the	International	Classification	of	Diseases	for	Oncology	(ICDO	version	2	or	3	
according	to	the	year	of	diagnosis)	and	coded	all	death	certificate	reports	according	to	
the	ICD	version	corresponding	to	the	year	of	death.	All	analyses	were	conducted	using	
only	confirmed	cancer	reports.		If	the	same	second	cancer	was	reported	on	both	a	
pathology	report	and	on	a	death	certificate	as	well,	we	used	the	incident	cancer	
confirmed	by	the	pathology	report	as	the	preferred	source	for	purpose	of	analysis,	unless	
we	were	specifically	analysing	mortality	patterns.	The	end	of	the	follow-up	varied	
depending	upon	the	type	of	analysis.	For	mortality	analyses,	the	end	of	follow-up	was	the	
date	of	the	most	recent	deaths	reported	by	the	NDI.	The	end	of	follow-up	for	the	
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incident	cancers	was	based	on	the	date	of	the	most	recent	survey	available	at	the	time	of	
the	analysis.	
2.6	Treatment	
2.6.1	Radiotherapy	
Most	hereditary	patients	(85%)	in	this	cohort	were	treated	with	radiotherapy	
whereas	non-hereditary	patients	were	not	(18%).	Patients	were	treated	typically	with	
external	beam	radiotherapy	(90%),	radioactive	plaques	(1%)	or	both	(9%).		Before	1960,	
most	patients	received	external	orthovoltage	x-irradiation.	After	1960,	the	beam	
energies	increased,	and	patients	were	treated	with	22	to	23	MV	Betatron	megavoltage	
photons	or	cobalt-60	gamma	rays.		The	higher	energy	beams	deposited	more	radiation	at	
the	eye	with	somewhat	less	scatter	radiation	to	surrounding	normal	tissues.	
We	collaborated	with	the	Medical	Physics	department	at	M.D.	Anderson	Medical	
Center	(Houston,	Texas)	to	estimate	the	sources	of	scatter	radiation	from	a	typical	
radiation	treatment	to	organs	in	the	body	of	a	1-year	old	and	an	infant	(6	months)	with	
RB.	Based	on	the	available	radiation	records,	medical	physicists	used	a	water	phantom	to	
measure	the	scatter	radiation	to	the	patients	from	three	potential	sources	(radiation	
leakage	from	the	collimator	of	the	external	beam	machine,	leakage	from	the	head	of	the	
machine,	and	scatter	from	within	the	body	from	the	radiotherapy)	for	the	various	
external	beam	energies.		These	measurements	were	then	applied	to	mathematical	
phantoms	that	could	be	scaled	to	the	size	of	the	child	being	treated	taking	into	account	
the	field	size	(Stovall	et	al.,	2006).		Typical	radiation	scatter	doses	to	organ	sites	are	
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presented	in	Table	2.1	for	a	one-year	old	treated	for	RB	with	Orthovoltage	and	Betatron	
radiotherapy.		These	dose	data	permitted	us	to	categorise	patients	according	to	whether	
their	second	cancer	was	heavily,	moderately	or	lightly	irradiated	as	well	as	diagnosed	in	
or	out	of	the	radiation	field.	
	
	
Table	2.1	Typical	Radiation	Doses	(Gray)*	to	organ	sites	in	a	1-year	old	
Organ	site	 	 Orthovoltage	(<1960)		 					Betatron	³1960	
	
Brain	 	 	 	 3.6	 	 	 1.6	
Eye	treated	 	 	 60	 	 	 45	
Eye	untreated	 	 18	 	 	 34	
	Nasal	region			 	 34	 	 	 3.2	
	Salivary	 	 	 4.3	 	 	 1.6	
Head	(soft	tissue)	 	 22	 	 	 11	
Facial	bones	 	 	 28	 	 	 	8	
	Thyroid	 	 	 2.0	 	 	 0.9	
	Lung	 	 	 	 0.5	 	 	 0.4	
	Breast	 	 	 0.4	 	 	 0.4	
Kidney	 	 	 0.1	 	 	 0.3	
Stomach	 	 	 0.2	 	 	 0.4	
Colon	 	 	 	 0.1	 	 	 0.2	
Bladder	 	 	 0.1	 	 	 0.2	
Uterus	 	 	 0.1	 	 	 0.2	
Bone	marrow		 	 1.2	 	 	 1.0	
*	Left	eye	treated,	4	cm	x	4cm,	50	Gy	given	dose	to	lateral	&	nasal	fields	
Source:	personal	communication	from	Marilyn	Stovall,	MD	Anderson	Cancer	Center	
2.6.2	Chemotherapy	
Twenty-eight	percent	of	patients	in	cohorts	1	and	2	were	treated	with	
chemotherapy	and	88%	of	these	patients	were	also	treated	with	radiotherapy.		Beginning	
in	the	1950’s	through	1970,	RB	patients	in	this	cohort	received	an	alkylating	agent	called	
	 40	
TEM	(Triethylenemelamine).	After	1970,	survivors	were	treated	with	a	range	of	other	
alkylating	agents,	including	nitrogen	mustard,	cyclophosphamide	and	thiotepa.	Very	few	
patients	(2%)	who	received	chemotherapy	were	treated	with	non-alkylating	agent		
chemotherapy	in	this	cohort.	Because	the	main	focus	of	the	study	of	second	cancers	in	
RB	survivors	was	risk	in	relation	to	radiation,	little	emphasis	was	placed	on	collecting	
details	of	the	chemotherapy	other	than	name	of	agents	and	dates.	In	total,	there	were	36	
different	combinations	of	chemotherapeutic	agents	that	we	grouped	into	six	categories	
based	on	their	toxicity.	Dose	data	were	generally	not	available.	If	we	decide	in	the	future	
to	conduct	another	case-control	study	of	sarcomas,	where	we	have	noted	an	increased	
risk	related	to	chemotherapy	in	addition	to	radiation,	then	we	would	attempt	to	retrieve	
information	on	chemotherapy	dose	from	hospital	records.	We	would	have	to	conduct	a	
small	feasibility	study	first	to	find	out	whether	the	records	are	still	available	and	the	level	
of	detail	provided.	
2.7	Statistical	Methodology	
The	purpose	of	the	analyses	was	to	quantify	the	effects	of	treatment	on	the	risk	
of	a	second	cancer	in	the	RB	cohort.	The	majority	of	the	analyses	evaluated	the	risk	of	
incident	second	cancers	in	the	cohort.	We	used	rates	from	two	US	registry	sources	
(Connecticut	Tumor	Registry	[1935-72]	and	the	SEER	9	registries	[1973-present]	to	
calculate	expected	number	of	cancers.	The	Connecticut	Registry	was	used	because	it	was	
the	only	US	cancer	registry	with	data	as	far	back	as	1935.	In	addition,	the	population	of	
Connecticut	was	similar	racially,	ethnically	and	economically	to	that	of	New	York	and	
Boston,	where	the	cohort	was	treated.	We	also	used	the	SEER	nine	registries	to	derive	
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expected	numbers	of	cancers	because	it	provided	a	larger	population	base	than	
Connecticut.	Unless	otherwise	specified	in	a	particular	analysis,	all	person-year	accrual	
began	one	year	after	diagnosis	of	RB	and	ended	at	date	of	second	cancer	diagnosis,	date	
of	death,	date	of	last	contact,	or	end	of	study	date,	whichever	occurred	earliest.		We	
excluded	the	person	time	and	events	during	the	first	year	after	RB	diagnosis	because	we	
wanted	to	exclude	any	simultaneously	diagnosed	cancers	as	well	as	deaths	due	to	RB.		
For	analyses	that	investigated	the	specific	causes	of	death	among	RB	patients,	we	
compared	the	causes	of	death	in	the	cohort	with	the	US	mortality	rates.	As	with	the	
incidence	analyses,	follow-up	began	one	year	after	RB	diagnosis	but	ended	on	the	date	
the	patient	was	last	known	to	be	alive,	date	of	death	or	end	of	follow-up	(date	of	the	NDI	
search),	whichever	occurred	earliest.		As	with	the	incident	analyses,	we	excluded	the	
person	time	and	events	during	the	first	year	after	RB	diagnosis	because	we	wanted	to	
exclude	any	simultaneously	diagnosed	cancers	as	well	as	deaths	due	to	RB.	
The	specific	methods	used	in	both	types	of	analyses	are	described	below	and	
within	each	chapter.	
2.7.1	Standardised	incidence	ratio	(SIR)		
We	estimated	SIRs	and	95%	confidence	intervals	(CI)	for	the	risk	of	second	
cancers	compared	with	the	incidence	of	these	cancers	in	the	general	population.		We	
divided	the	observed	number	of	second	cancers	by	the	expected	number	of	cancers	
based	on	age,	sex	and	5-year	calendar	year-specific	incidence	rates	from	two	sources	–	
the	Connecticut	Tumour	Registry	rates	for	1935-1972	and	SEER	rates	(Surveillance,	
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Epidemiology	and	End	Results	program)	for	1973	onwards.	Rates	were	not	adjusted	for	
race	or	ethnicity.	Confidence	intervals	were	calculated	using	the	Wald	method	(Breslow	
and	Day,	1987).	We	compared	the	incidence	of	observed	second	cancers	relative	to	
those	expected	from	the	general	population,	because	the	general	population	rates	
provided	the	most	stable	rates	for	comparison	of	risk	for	many	different	types	of	second	
cancers,	including	histologic	types	of	soft	tissue	sarcomas.	Comparison	of	SIRs	for	specific	
characteristics	of	RB	survivors	(e.g.	SIR	for	patients	treated	<1	year	of	age	RB	diagnosis	
versus	SIR	for	≥1	year	of	age)	was	based	on	the	chi-square	test	of	homogeneity	(Breslow	
and	Day,	1987).
	
2.7.2	Cumulative	incidence	
We	used	the	Gooley	method	(Gooley	et	al.,	1999)	to	calculate	the	cumulative	
incidence	per	cent	and	95%	CI	of	second	cancers	after	RB	diagnosis	up	to	50	years	later.		
For	the	cumulative	incidence	of	all	second	cancers	combined,	that	is	the	probability	of	
developing	a	second	cancer	by	the	number	of	years	after	treatment	for	RB,	deaths	from	
RB	and	all	other	non-second	cancer	causes	were	considered	as	a	competing	risk.	For	the	
cumulative	incidence	of	a	specific	second	cancer,	deaths	from	other	second	cancers	were	
treated	as	a	competing	risk,	because	deaths	from	other	causes	would	have	precluded	the	
occurrence	of	the	specific	cancer	of	interest.	Practically,	this	means	that	patients	were	no	
longer	at	risk	from	the	time	of	competing	event.		P-values	were	calculated	according	to	
the	method	of	Gray	(Gray,	1988)	and	conducted	using	the	cmprsk	in	R	statistical	software	
(http://www.r-project.org).		
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2.7.3	Standardised	mortality	ratio	and	cumulative	mortality	
We	estimated	standardised	mortality	ratios	and	exact	Poisson	95%	CIs	(Monson,	
1974)	by	dividing	the	observed	number	of	deaths	by	the	expected	number	from	the	
general	population	by	applying	US	mortality	rates	(by	5-year	age,	5-calendar	year	and	
sex-specific	categories)	to	the	appropriate	person-time	accrued	by	the	RB	survivors.		US	
mortality	rates	were	available	from	1925	onwards.	For	the	few	survivors	diagnosed	prior	
to	1925,	we	reset	their	start	date	to	January	1,	1925.			
Cause-specific	cumulative	mortality	up	to	50	years	after	RB	diagnosis	was	
calculated	using	the	cmprsk	program	in	R	statistical	software	(http://www.r-project.org).		
Causes	of	death	from	other	than	the	specific	second	cancers	of	interest	were	treated	as	
competing	risks.		
2.7.4	Excess	absolute	risk	(incidence	and	mortality)	
We	calculated	the	excess	absolute	risk	(EAR)	as	the	observed	number	of	second	
cancers	minus	the	expected	number	of	second	cancers	divided	by	the	person	years	at	
risk	times	10,000.	This	estimate	provided	the	burden	of	incident	second	cancers	or	
burden	of	mortality	from	specific	second	cancers.		
2.7.5	Univariate	and	multivariate	analyses	
In	order	to	evaluate	the	effect	of	modifying	variables	such	as	age	at	exposure,	
year	of	exposure,	sex	and	type	of	treatment	on	the	risk	of	second	cancers,	we	fitted	a	
Poisson	regression	model	that	evaluated	the	association	of	each	variable	individually	
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(unadjusted	or	univariate	relative	risk)	and	simultaneously	adjusted	for	all	other	variables	
in	the	model	(adjusted	or	multivariate	risk)	using	Epicure	software	(Preston	DL,	1993).	
The	statistical	significance	of	each	variable	was	assessed	by	a	likelihood	ratio	test	
comparing	the	model	with	the	variable	of	interest	to	the	model	without	the	variable.	
Two-sided	P	values	<0.05	were	considered	statistically	significant.	The	variables	were	
stratified	according	to	hypotheses	associated	with	particular	attributes.	For	example,	
calendar	year	of	RB	diagnosis	was	stratified	into	three	categories,	i.e.,	before	1960,	1960-
69	and	1970+	to	reflect	radiotherapy	treatment	trends.	Prior	to	1960,	orthovoltage	
external	beam	was	used	and	after	1960,	cobalt-60	and	betatron	external	beam	was	use.	
Although	chemotherapy	began	to	be	used	more	commonly	after	1990,	there	were	too	
few	survivors	treated	exclusively	with	chemotherapy	during	this	time	period	to	be	able	to	
evaluate	the	risk	of	second	cancers	with	modern	chemotherapy.	The	majority	of	
survivors	in	the	cohort	were	treated	in	the	1960s.		Age	at	RB	diagnosis	was	classified	as	
<12	months,	12-23	months	and	≥24	months.	An	early	analysis	of	the	New	York	cohort	of	
survivors	(Abramson	and	Frank,	1998)	indicated	that	children	with	RB	treated	at	<12	
months	of	age	are	more	susceptible	to	the	harmful	effects	of	radiotherapy	to	induce	
second	cancers	compared	with	older	children.	
For	the	detailed	chemotherapy	analyses	of	risk	of	second	cancers	(see	chapter	8),	
we	used	a	Cox	proportional	hazards	regression	model	with	age	as	the	time	scale	to	
investigate	the	risk	of	second	cancers	in	different	treatment	subgroups	(e.g.	with	and	
without	alkylating	agents,	TEM)	using	SAS,	version	9.3.	These	models	were	stratified	by	
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calendar	year	of	diagnosis	to	account	for	the	temporal	changes	in	treatment	practices	for	
RB.		Two-sided	P	values	<0.05	were	considered	statistically	significant.	
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Chapter	3. Risk	of	lung	cancer	and	smoking	
Kleinerman	RA,	Tarone	RE,	Abramson	DH,	Seddon	JM,	Li	FP,	Tucker	MA.	Hereditary	
retinoblastoma	and	risk	of	lung	cancer.	J	Natl	Cancer	Inst	92;2037-39,	2000	
3.1	Introduction	and	rationale	
Somatic	mutations	in	the	RB1	gene	contribute	to	the	risk	of	lung	cancer	and	these	
mutations	have	been	identified	in	small	cell	lung	cancer	(Harbour	et	al.,	1988).		However,	
at	the	time	of	this	study,	it	had	been	hypothesised	but	was	unknown	whether	RB	
survivors	were	at	increased	risk	of	lung	cancer,	because	none	had	been	reported	in	the	
previous	mortality	analysis,	likely	due	to	the	median	years	of	follow	up	the	cohort	of	only	
17	years	(Eng	et	al.,	1993).	Because	lung	cancer	is	a	fatal	cancer,	we	investigated	risk	of	
dying	of	lung	cancer	in	our	cohort	of	RB	survivors.	This	chapter	describes	this	
investigation.	
3.2	Methods	
We	conducted	a	search	of	the	National	Death	Index	(NDI)	to	identify	new	causes	
of	death	through	the	end	of	1997.	This	added	7	more	years	of	follow	up	since	the	
previous	NDI	search	in	1990	that	was	used	as	the	basis	for	the	publication	of	the	original	
study	of	this	cohort	(Eng	et	al.,	1993).	The	entire	cohort	1	was	submitted	to	the	NDI	to	
identify	new	deaths	in	the	cohort.	At	the	time	of	the	analysis,	cohort	2	was	not	yet	
available	for	analysis.	If	the	subject	was	not	matched	to	a	record	in	the	NDI,	we	assumed	
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that	they	were	still	alive.	For	subjects	who	matched,	we	used	the	underlying	cause	of	
death	for	analysis.	
We	evaluated	the	risk	of	dying	from	lung	cancer	in	1604	RB	patients	(964	
hereditary	and	640	non-hereditary).	Overall,	16.5%	(n=264)	of	the	survivors	were	40	
years	and	older	(median	age=24	years)	and	24%	had	died	(n=381).	Vital	status	differed	by	
hereditary	status	with	a	larger	proportion	of	deaths	in	the	hereditary	patients	compared	
with	non-hereditary	patients	(32%	vs.	11%)	(Table	3.1).			
Table	3.1	Characteristics	of	1604	one-year	survivors	of	retinoblastoma	
Characteristic	 Hereditary	n=964	 Non-hereditary	n=640	
Sex	 No.	%	 No.	%	
Male	 513	(53.2)	 334	(52.2)	
Female	 451	(46.8)	 306	(47.8)	
Age	at	last	follow	up	 	 	
<40	years	 825	(85.6)	 515	(80.5)	
40+	years	 139	(14.4)	 125	(19.5)	
Vital	status	 	 	
Alive		 604	(62.7)	 519	(81.1)	
Lost	to	follow	up	 51	(5.3)	 49	(7.7)	
Death	 309	(32.1)	 72	(11.3)	
	
We	conducted	a	Standardised	Mortality	Ratio	(SMR)	analysis	by	dividing	the	
observed	deaths	in	the	RB	cohort	by	the	expected	number	of	deaths	from	the	general	
population	based	on	the	person-years	at	risk	and	adjusted	for	age,	sex	and	calendar	year	
of	the	death.	Analyses	were	stratified	by	hereditary	status.	
3.3	Main	findings	
Overall,	we	found	an	increased	risk	of	death	from	all	cancers	in	hereditary	
patients	(observed=129,	SMR=47,	95%CI	39-56)	compared	with	non-hereditary	patients	
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(observed	=10,	SMR=3.8,	95%CI	1.8-7.0).	Over	the	7	years	of	additional	deaths	from	NDI	
since	the	previous	study	by	Eng	et	al	(Eng	et	al.,	1993),	50	new	deaths	had	occurred,	
mainly	cancers	of	the	bone	(n=12),	connective	tissue	(n=13)	and	lung	(n=5).		We	noted	a	
statistically	significantly	elevated	risk	of	dying	from	lung	cancer	(observed=5,	
expected=0.33,	SMR=15.2,	95%CI	4.9-35).		All	of	the	lung	cancer	deaths	occurred	in	
hereditary	patients	and	only	2	of	the	5	were	diagnosed	in	patients	who	had	received	
radiotherapy	(Table	3.2).		Additionally,	all	five	deaths	were	in	females,	and	75%	of	those	
with	histology	were	small	cell	carcinomas.		We	were	able	to	document	smoking	history	
and	found	4/5	cases	had	smoked.		Most	notably,	3/5	deaths	were	in	women	40	years	of	
age	or	younger.		
Table	3.2	Characteristics	of	the	lung	cancer	cases	
Obs.	 Sex	
Radio-
therapy	
Lung	cancer	
histology	
Age	at	
death,	
years	 Smoking	history	
1	 Female	 Yes	 Unknown	 39	 60	pack-yrs	
2	 Female	 No	 Small	cell/large	
cell	mixed	
40	 19	pack-yrs	
3	 Female	 Yes	 Small	cell	 40	 20	pack-yrs	
4	 Female	 No	 Adenocarcinoma	 52	 Non-smoker	
5	 Female	 No	 Small-cell	 64	 Modest	smoker	
for	many	years	
	
Although	there	have	been	case	reports	of	lung	cancer	in	RB1	mutation	carriers	
and	mostly	in	males	(Smith	and	Bedford,	1976),	a	UK	study	of	4101	relatives	of	RB	
patients	including	117	RB1	carriers	reported	10	lung	cancers	in	RB1	mutation	carriers	
with	a	similar	SMR	to	our	study	(SMR=15.4,	95%CI	6.6-30)	(Sanders	et	al.,	1989).		Overall,	
our	results	together	with	the	earlier	reports	establish	that	germline	RB1	mutations	
	 49	
confer	an	increased	risk	of	dying	of	lung	cancer.		Previous	reports	of	lung	cancer	in	males	
likely	points	to	a	chance	occurrence	of	lung	cancer	in	females	in	our	study	and	could	be	
due	to	higher	smoking	rates	in	men	than	women	in	earlier	time	periods.	
The	number	of	lung	cancer	deaths	was	small,	however,	they	were	only	diagnosed	
in	hereditary	patients.	Four	of	the	five	lung	cancer	deaths	were	confirmed	by	pathology	
reports	as	well.		Several	factors	support	an	increased	susceptibility	of	carriers	of	a	RB1	
germline	mutation	to	smoking-related	lung	cancer.		These	include	the	young	age	at	onset	
of	lung	cancer,	histology	(small	cell	lung	cancer),	and	positive	smoking	history.	Although	
tobacco	use	in	the	entire	cohort	was	incomplete	and	this	is	a	major	factor	for	lung	
cancer,	we	were	able	to	obtain	some	preliminary	cigarette	smoking	data	from	a	
telephone	survey	of	the	cohort	conducted	in	2000	that	indicated	that	hereditary	patients	
were	no	more	likely	to	smoke	than	non-hereditary	patients,	yet	no	lung	cancers	deaths	
were	diagnosed	in	the	non-hereditary	patients	(Foster	et	al.,	2006).	Smoking	rates	of	17%	
in	both	the	hereditary	and	non-hereditary	survivors	were	similar	to	the	US	population.	
3.4	Significance		
	 This	study	provided	epidemiological	evidence	for	increased	risk	of	lung	
cancer	mortality	in	RB	survivors,	which	had	been	hypothesised	based	on	previous	
biologic	evidence	of	RB1	gene	somatic	mutations	identified	in	the	pathway	of	small	cell	
lung	cancer.		The	results	from	this	study	(Kleinerman	et	al.,	2000)	were	cited	in	an	
editorial	in	2004	as	evidence	of	a	clinical	relationship	between	a	RB	germline	mutation	
and	small	cell	lung	cancer	that	was	originally	identified	through	a	molecular	genetic	
study:			“For	many	years,	the	intuitive	notion	has	been	that	a	subset	of	tobacco	users	
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exhibits	a	genetic	susceptibility	to	developing	lung	cancer,	but	there	was	never	evidence	
to	directly	link	a	specific	genetic	locus	to	this	elevated	risk.	The	RB1	gene	may	now	serve	
as	yet	another	paradigm	for	the	concept	of	a	genetic	susceptibility	locus	for	lung	and	
bladder	cancer	among	tobacco	users”	(Kaye	and	Harbour,	2004).	
3.5	Public	Health	Message		
Survivors	with	hereditary	RB	should	be	targeted	for	smoking	cessation	because	
they	are	at	greater	risk	of	dying	from	lung	cancer.		On	the	RB	study	website,	we	have	
provided	recommendations	for	survivors	to	quit	smoking	as	well	as	sources	to	contact	for	
support.		
3.6	Role	in	the	study	
Role:	I	initiated	the	study,	analysed	the	data	in	consultation	with	Dr	Tarone	and	
drafted	the	manuscript.	Study	team:	Dr	Tarone	was	the	statistician,	Drs	Abramson	and	
Seddon	were	the	clinical	collaborators	and	provided	the	patients;	Drs	Li	and	Tucker	were	
the	senior	study	investigators.	My	contribution:	75%		
3.7	Publication	
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Chapter	4. Risk	of	second	cancers	due	to	radiotherapy	
Kleinerman	RA,	Tucker	MA,	Tarone	RE,	Abramson	DH,	Seddon	JM,	Stovall	M,	Li	
FP,	Fraumeni,	JF,	Jr.		Risk	of	new	cancers	in	long-term	survivors	of	retinoblastoma:	An	
extended	follow-up.	J	Clin	Oncol	2005;23:2272-9	
4.1	Introduction	and	rationale	
	 Based	on	previous	studies	in	this	cohort	indicating	statistically	significant	
increases	in	second	cancers	related	to	past	radiotherapy	for	RB	(Eng	et	al.,	1993)	(Wong	
et	al.,	1997),	and	the	hypothesis	that	the	risk	of	second	epithelial	cancers	would	be	
expected	to	increase	above	background	rates	as	the	cohort	ages	(Kaye	and	Harbour,	
2004),	we	surveyed	the	cohort	in	2000-2001	to	update	the	information	on	second	
cancers.		In	this	analysis,	we	provided	new	information	on	cancer	risk	based	on	seven	
additional	years	of	follow-up.	This	chapter	provides	a	summary	of	those	findings.	
4.2	Methods	
This	study	was	conducted	in	cohort	1	only	(n=1601	survivors),	because	cohort	2	
was	not	available	for	analysis.	We	updated	the	vital	status	and	the	contact	information	
for	survivors	in	2000.	Next,	I	designed	a	survey	to	be	conducted	among	living	members	of	
the	cohort	(computer	aided	telephone	interview)	(Appendix	A.1)	to	ascertain	basic	
cancer	risk	factor	information	and	obtain	diagnoses	of	new	cancers.	There	were	1100	
living	individuals	and	we	were	able	to	successfully	contact	875	(75%)	(Foster	et	al.,	2006).		
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At	the	time	of	the	survey	conducted	in	2000	(Foster	et	al,	2006)	for	cohort	1,	we	
found	through	various	tracing	efforts	that	1169	(73%)	of	subjects	were	alive,	385	(24%)	
were	deceased	and	47	(2.9%)	were	lost	to	follow	up.	Lost	to	follow-up	was	defined	as	any	
study	subjects	for	whom	we	had	no	information	that	they	were	alive	or	dead	based	on	
linkages	with	the	National	Death	Index	and	Social	Security	Administration.		Of	the	1169	
eligible	subjects,	875	(75%)	responded	to	the	computer-aided	telephone	questionnaire	
and	294	(25%)	did	not	respond.	Non-responders	did	not	differ	significantly	from	
responders	by	year	of	birth,	age	at	survey,	sex,	hereditary	status,	age	at	RB	diagnosis	or	
treatment.	However,	there	were	slightly	more	respondents	who	reported	a	family	history	
of	RB	(17.4%	vs.	11.9%)	indicating	that	perhaps	those	with	a	second	cancer	were	more	
likely	to	respond	to	the	survey.	However,	the	SIR	for	all	second	cancers	combined	for	
hereditary	and	non-hereditary	survivors	as	well	the	SIR	for	bone	cancer	(Kleinerman	et	al	
2005)	were	very	similar	to	those	reported	by	the	Dutch	RB	cohort	(Marees	et	al.,	2008),	
which	was	similar	to	our	study	in	terms	of	treatment	of	RB	patients,	making	it	less	likely	
that	there	was	a	bias	due	to	over-reporting	of	second	cancers.	It	remains	a	concern	today	
that	survivors	with	a	second	cancer	are	more	likely	to	respond	than	those	without	a	
second	cancer.	They	are	more	likely	to	be	motivated	to	respond	to	a	survey	as	well	as	
likely	being	under	surveillance	for	other	tumors,	such	as	non-melanoma	skin	cancers.		
We	confirmed	reports	of	new	primary	cancers	by	pathology	reports	(60.7%),	
hospital	or	physician	records	(20.6%),	death	certificates	(15.5%)	and	autopsy	reports	
(3.2%).		All	of	the	cancers	were	coded	to	ICDO	version-2	or	-3	for	topography	only.	
Although	we	had	pathology	reports	with	histology	coded,	we	did	not	use	histology	in	this	
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analysis,	because	the	expected	rates	from	the	Connecticut	Tumour	Registry	and	SEER	
were	based	on	topography	only.			
I	worked	with	our	colleagues	at	MD	Anderson	Cancer	to	estimate	typical	radiation	
scatter	doses	to	all	organs	in	the	body	for	an	infant	and	for	a	one-year	old	patient	
receiving	radiotherapy	for	RB	(see	Chapter	2,	Table	2.1).	The	dose	data	allowed	us	to	
stratify	the	subsequent	cancer	sites	into	three	major	exposure	groups	(heavily	irradiated	
sites,	≥	1	Gy;	moderately	irradiated	sites,	0.4-1.0	Gy;	and	lightly	irradiated	sites,	<0.4	Gy),	
in	order	to	evaluate	how	risk	varied	by	dose	category.		
Accrual	of	person-years	began	1	year	after	RB	diagnosis	and	ended	at	date	of	
death,	second	cancer,	date	last	known	alive	or	December	30,	2000,	which	ever	occurred	
earliest.		As	mentioned	earlier,	we	used	a	very	broad	definition	of	lost	to	follow	up.	These	
subjects	were	mainly	those	for	whom	we	could	not	contact	due	to	lack	of	a	good	address	
or	telephone	number,	nor	could	we	get	a	positive	match	with	either	the	social	security	
administration	presumed	living	search	or	death	master	file,	nor	link	with	the	National	
Death	Index.	However,	even	if	we	were	unable	to	contact	a	subject,	if	they	were	matched	
with	the	social	security	presumed	living	search,	we	considered	them	alive	and	not	lost	to	
follow	up.	
We	calculated	SIRs	as	the	ratio	of	observed	cancers	to	expected	cancers	using	5-
year	age-specific,	sex-specific	and	5-year	calendar	year-specific	rates	from	the	
Connecticut	Tumour	Registry	and	SEER.		Excess	absolute	rates	were	calculated	as	
(number	of	observed	cancers	minus	expected	cancers	divided	by	person-years	at	risk)	
times	10,000.	Cumulative	incidence	rates	were	estimated	with	adjustment	for	competing	
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risk	of	death	for	1)	hereditary	status	(hereditary,	non-hereditary),	2)	radiotherapy	among	
hereditary	survivors	(yes/no),	and	3)	type	of	radiotherapy	(Orthovoltage	and	Cobalt-60	or	
Betatron)	among	hereditary	survivors.	
4.3	Main	findings	
At	the	end	of	follow-up,	more	non-hereditary	than	hereditary	survivors	were	alive	
(84.8%	vs.	64.6%),	and	only	28	hereditary	(2.9%)	and	25	(3.9%)	non-hereditary	survivors	
were	lost	to	follow-up.	The	average	years	of	follow	up	were	25.2	years	for	hereditary	and	
29.5	years	for	non-hereditary.		At	the	time	of	this	follow-up,	22%	of	hereditary	and	35%	
of	non-hereditary	were	over	age	40,	the	primary	age	group	of	interest	for	epithelial	
tumours.		Selected	characteristics	of	the	study	population	are	presented	in	Table	4.1.	
Table	4.1	Selected	characteristics	of	1-year	survivors	of	retinoblastoma	
Characteristic	 Hereditary	(%)	 Non-Hereditary	(%)	
No.	of	subjects	 963	(100)	 	 638	(100)	
Laterality	 	 	 	
				Unilateral	 	 47	(4.9)	 	 638	(100)	
				Bilateral	 	 916	(95.1)	 	 0	(0.0)	
Sex	 	 	 	 	
			Male	 	 512	(53.2)	 	 334	(52.3)	
			Female	 	 451	(46.8)	 	 304	(47.7)	
Age	at	Rb	diagnosis		 	 	 	
		<	1	yr	 	 545	(56.6)	 	 140	(21.9)	
					1	yr	 	 267	(27.7)	 	 197	(30.9)	
					2	yr	 	 110	(11.4)	 	 159	(24.9)	
					3—7	yrs	 	 41	(4.3)	 	 142	(22.3)	
Yr.	of	Rb	diagnosis	 	 	 	
		1914-49	 106	(11.0)	 	 75	(11.8)	
		1950-59	 	 200	(20.8)	 	 100	(15.7)	
		1960-69	 	 312	(32.4)	 	 198	(31.0)	
		1970-79	 	 253	(26.3)	 	 192	(30.1)	
		1980-84	 	 92	(9.5)	 	 73	(11.4)	
Family	history	of	Rb	 	 	 	
	Yes	 	 283	(29.3)	 	 0	(0.0)	
	No	 	 497	(51.6)	 	 499	(78.1)	
	Uncertain	 	 183	(19.1)	 	 139	(21.9)	
Treatment		 	 	 	
		Surgery	 	 95	(9.9)	 	 480	(75.2)	
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		Chemotherapy		 16	(1.6)	 	 38	(6.0)	
		Radiation	 	 466	(48.4)	 	 67	(10.5)	
		Radiat/Chemo	 383	(39.8)	 	 47	(7.4)	
		Unknown	 	 4	(0.3)	 	 6	(0.9)	
Any	Radiotherapy	 	 	 	
			Yes	 	 849	(88.2)	 	 114	(17.5)	
			No	 	 114	(11.8)	 	 524	(82.5)	
	
In	the	additional	7	years	of	follow-up	since	1993-2000,	78	new	second	cancers	
were	confirmed,	and	one-half	of	these	were	either	bone	or	soft	tissue	sarcomas.		Overall,	
there	was	a	significantly	elevated	risk	for	second	cancers	in	the	hereditary	survivors	
(SIR=19,	95%	CI	16-21;	Observed=260)	compared	with	a	non-significant	risk	in	the	non-
hereditary	group	(SIR=1.7,	95%	CI	0.7-2.0;	Observed=17)	(Table	4.2).		In	the	hereditary	
survivors,	significant	SIRs	over	100	were	noted	for	cancers	of	the	bone,	connective	tissue,	
eye	and	orbit	and	nasal	cavities.	Risks	were	also	elevated	(SIR	>10)	for	pineoblastoma,	
melanoma,	and	cancers	of	the	brain,	buccal	cavity	and	corpus	uteri.		Lower	but	
significantly	increased	risks	(SIR<10)	were	also	noted	for	cancers	of	the	lung,	breast	and	
colon.		
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Table	4.2	Risk	of	new	cancers	in	1-year	survivors	of	retinoblastoma	by	hereditary	status.	
	 Standardised	Incidence	Ratios*	
No.	of	persons	 	 						963	 	 	 	 						638	 	
Person	years	at	risk	 		 	25,309	 		 		 		 	18,972	 		
	 Hereditary	 	 Non-hereditary	
Cancer	Site	(ICD-0	Classification)	 O	 E	 SIR	(95%	CI)	 	 O	 E	 SIR	(95%	CI)	
All	sites
†
	 260	 13.9	 19	(16-21)	 	 17	 13.9	 1.2	(0.7-2.0)	
Bone	(170)	 75	 0.21	 360	(283-451)	 	 0	 0.16	 0.0	(0.0-22.6)	
Connective	and	soft	tissue	(171,	192.4,	192.5)	 34	 0.28	 122	(84-170)	 	 0	 0.22	 0.0	(0.0-16.8)	
Nasal	Cavities	(160)	 32	 0.03	 1111	(760-1569)	 	 0	 0.03	 0.0	(0.0-135)	
Cutaneous	melanoma	(173	and	M872-878)	 29	 1.05	 28	(18-40)	 	 0	 1.00	 0.0	(0.0-3.7)	
Eye	and	orbit	(190)	 17	 0.06	 266	(155-426)	 	 0	 0.05	 0.0	(0.0-81)	
Brain,	CNS	(191-192.0-.3,192.9)	 10	 0.74	 13.6	(6.5-25)	 	 2	 0.58	 3.43	(0.4-12)	
Female	Breast	(174)	 10	 2.52	 3.96		(1.9-7.3)	 	 7	 2.46	 2.84	(1.1-5.9)	
Corpus	uteri	(182)	 7	 0.35	 20	(8.0-41)	 	 0	 0.35	 0.0	(0.0-10)	
Buccal	cavity	(140-149)‡	 7	 0.34	 20	(8.2-42)	 	 0	 0.37	 0.0	(0.0-9.9)	
Lung	(162)	 5	 0.84	 5.94	(1.9-14)	 	 0	 1.11	 0.0	(0.0-3.3)	
Pineoblastoma	(194.4)	 5	 0.06	 90.8	(29-212)	 	 0	 0.04	 0.0	(0.0-93)	
Colon	(153)	 3	 0.48	 6.28	(1.3-18)	 	 0	 0.58	 0.0	(0.0-6.3)	
Hodgkin	lymphoma	(M9650-67)	 3	 0.88	 3.4	(0.7-10)	 	 1	 0.70	 1.4	(0.04-8.0)	
Bladder	(188,	189.9)	 2	 0.32	 6.15	(0.7-22)	 	 0	 0.41	 0.0	(0.0-8.8)	
Leukemia	(204-207)	 2	 0.89	 2.25	(0.3-8.1)	 	 1	 0.66	 1.47	(0.04-8.2)	
Excess	absolute	risk	per	10,000	person-years§	 	 	 97.2	 	 	 	 1.63	
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Comparison	of	hereditary	patients	who	did	and	did	not	receive	radiotherapy	
revealed	that	hereditary	patients	treated	without	radiation	still	had	a	7-fold	increased	
risk	of	second	cancers	compared	with	the	general	population	(SIR=6.9,	95%	CI	4.1-11).		
Radiotherapy	further	increased	the	risk	by	3-fold	in	hereditary	patients	(SIR	22	vs.	
SIR=6.9).		When	we	stratified	the	organ	sites	by	heavily,	moderately	and	lightly	
irradiated,	the	risk	patterns	were	consistent	with	the	highest	risks	noted	for	the	heavily	
irradiated	sites	with	the	exception	of	thyroid	cancer	that	was	not	significantly	elevated.	
Interestingly,	cutaneous	melanoma	was	significantly	elevated	in	hereditary	patients	both	
with	and	without	radiation	exposure.	The	risk	for	corpus	uteri	was	also	significantly	
increased	in	both	treatment	groups	as	well.		When	we	investigated	further,	we	found	
that	5/7	of	these	uterine	tumours	were	leiomyosarcomas,	a	rare	smooth	muscle	tumour.		
When	we	compared	risk	among	hereditary	patients	with	radiotherapy	treated	
with	and	without	chemotherapy,	we	noted	a	modest	difference	in	risk	for	all	cancers	
combined	(SIR=25,	95%CI	21-30	with	chemotherapy	vs.	SIR=19,	95%CI	16-23	without	
chemotherapy).		
The	cumulative	incidence	of	second	cancers	varied	by	hereditary	status,	
radiotherapy	status	and	type	of	radiotherapy	machine.		At	50	years	after	RB	diagnosis,	
there	was	a	36%	cumulative	risk	of	a	second	cancer	in	hereditary	compared	with	a	5.6%	
cumulative	risk	in	non-hereditary	survivors	(Figure	4.1).	Among	the	hereditary	survivors	
the	cumulative	incidence	reached	38%	(95%	CI	33%-44%)	and	21%	(95%	CI	9.4%-36%)	
respectively	for	those	with	and	without	radiotherapy,	based	on	a	small	number	of	50-
year	survivors	(Figure	4.2).	
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4.4	Significance	
This	analysis	provided	new	information	on	risks	of	epithelial	cancers	in	relation	to	
radiation	treatment	and	confirmed	previous	increases	in	second	cancers,	mainly	bone	
and	soft	tissue	sarcomas,	in	hereditary	survivors	(Kleinerman	et	al.,	2005).	When	treated	
with	radiotherapy,	hereditary	survivors	were	three	times	more	likely	to	develop	a	
subsequent	cancer	compared	with	hereditary	survivors	who	were	treated	without	
radiotherapy.	We	observed	the	highest	risks	for	cancer	of	organ	sites	that	received	the	
highest	doses.	At	50	years	after	RB	diagnosis,	one	out	of	three	hereditary	survivors	and	
one	of	out	of	20	non-hereditary	survivors	had	developed	a	subsequent	non-ocular	
cancer.		
One	of	the	main	reasons	for	undertaking	this	analysis	was	to	identify	the	risk	of	
epithelial	tumours	in	this	cohort,	especially	those	cancers	with	a	somatic	mutation	in	the	
RB1	pathway.	Although	based	on	small	numbers,	we	identified	new	risks	in	this	
population	for	cancer	of	the	salivary	gland,	tongue	and	nasopharynx.		All	of	these	three	
sites	received	high	doses	of	radiation	due	to	their	proximity	to	the	eye,	which	was	the	
target	of	radiation.		Salivary	gland	cancer	has	been	linked	previously	to	radiotherapy	in	
children	treated	for	enlarged	tonsils	(mean	dose=4.6	Gy)	and	tinea	capitis	(ringworm	of	
the	scalp)	(0.4	Gy)	(Ron,	2003),	which	was	consistent	with	the	radiation	dose	received	by	
those	sites	in	RB	patients	(mean	dose	1.6-4.2	Gy)	in	this	study.		Cancer	of	the	tongue	has	
been	associated	with	tobacco	smoking,	but	neither	of	the	two	survivors	smoked.	One	of	
two	nasopharyngeal	cancers	was	a	sarcoma.	All	of	these	three	types	of	cancer	occurred	
in	irradiated	hereditary	survivors,	supporting	a	link	with	radiation.		
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We	also	identified	new	increased	risks	for	uterine	cancer,	the	majority	of	which	
were	leiomyosarcomas	(LMS),	a	rare	smooth	muscle	tumour,	as	well	as	a	risk	for	colon	
cancer.	Doses	were	low	to	both	of	these	organs,	yet	the	SIRs	were	significantly	elevated.		
Increased	risks	for	bladder	cancer	have	been	reported	in	other	RB	cohorts	(Fletcher	et	al.,	
2004,	Marees	et	al.,	2008a)	but	only	two	bladder	cancers	were	diagnosed	in	this	cohort.		
Previously,	breast	cancer	was	significantly	elevated	only	in	the	non-hereditary	
survivors,	which	was	surprising	since	somatic	RB1	mutations	have	been	identified	in	
sporadic	breast	cancer	(Bosco	and	Knudsen,	2007).	In	the	current	analysis	we	found	
breast	cancer	to	be	significantly	elevated	in	both	hereditary	and	non-hereditary	
survivors,	but	among	the	hereditary	survivors,	it	was	only	significantly	elevated	only	in	
those	who	were	irradiated.		The	radiation	dose	to	the	breast	(mean	dose=	0.4	Gy)	in	RB	
survivors	is	consistent	with	the	doses	received	by	other	childhood	populations	that	have	
reported	increases	in	breast	cancer	in	adults	irradiated	for	suspected	enlarged	thymus	
glands	or	haemangioma	in	childhood	(Preston	et	al.,	2002).	
One	of	the	biggest	differences	with	this	analysis	compared	with	the	previous		
analyses	by	Wong	et	al	(Wong	et	al.,	1997)	was	a	decrease	in	the	cumulative	incidence	of	
second	cancers	at	50	years	from	50%	to	36%	in	hereditary	survivors	in	the	current	
analysis.	We	did	not	detect	a	change	in	the	cumulative	incidence	for	non-hereditary	
survivors.	The	previous	analysis	used	the	Kaplan	Meier	method,	whereas	the	Gooley	
method	that	we	used	in	the	current	analysis	likely	accounted	for	some	of	the	difference,	
because	it	takes	competing	risk	of	death	into	account.		We	also	had	accumulated	
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additional	person	years	in	this	analysis	compared	with	the	earlier	analysis	that	would	
have	led	to	more	stable	cumulative	risk	estimates	for	the	more	recent	time	period.		
We	found	a	lower	cumulative	incidence	for	hereditary	patients	treated	without	
radiation	compared	with	those	treated	with	radiation	(21%,	95%CI	9%-36%	vs.	38%,	
95%CI	33%-44%).		Although	patients	were	not	randomised	to	treatment	groups,	most	
patients	were	diagnosed	with	RB	at	approximately	the	same	age,	so	age	should	not	have	
confounded	the	cumulative	incidence	estimates.	If	the	two	treatment	groups	were	
markedly	different	ages	at	diagnosis	then	the	cumulative	incidences	could	not	be	
compared	because	they	would	not	have	the	same	opportunity	to	develop	second	cancers	
at	similar	ages.	
Interestingly,	we	noted	a	lower	cumulative	incidence	for	survivors	treated	with	
non-orthovoltage	radiotherapy	compared	with	orthovoltage	radiotherapy	(26%	vs.	33%),	
although	the	confidence	intervals	did	overlap.	There	is	less	scatter	radiation	associated	
with	non-orthovoltage	radiation	compared	with	orthovoltage	radiation.	However	
patients	were	treated	with	orthovoltage	in	earlier	time	periods	and	therefore	had		more	
time	to	develop	a	second	cancer,	so	this	could	account	for	some	of	the	difference	in	the	
cumulative	incidence.		
The	source	of	the	population	was	hospital-based	rather	than	population-based	
and	included	only	two	institutions	that	may	limit	the	generalisability	of	the	findings	from	
the	study	to	the	general	population.	The	cohort	was	not	representative	of	the	true	
proportion	of	hereditary	patients	in	the	general	population,	because	it	included	a	much	
larger	proportion	of	hereditary	compared	with	non-hereditary	survivors	typically	found	in	
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the	general	population.	Hereditary	patients	are	more	likely	to	develop	an	additional	
cancer	due	to	their	germline	mutation	and	this	could	have	biased	the	risk	estimates	
upwards.		However,	the	loss	to	follow-up	was	similar	in	both	groups	and	each	group	was	
independently	compared	with	the	general	population.	In	addition,	RB	is	a	rare	cancer	and	
second	cancers	are	rare,	so	the	inclusion	of	more	hereditary	survivors	increases	the	value	
of	the	population	to	identify	risks.	Treatment	differed	greatly	by	hereditary	status	with	
almost	all	hereditary	patients	receiving	radiotherapy	(85%)	compared	with	a	very	small	
proportion	of	non-hereditary	patients	treated	with	radiotherapy	(15%).	This	could	have	
confounded	the	results,	but	when	we	stratified	the	risks	by	radiation	dose	in	three	
categories	(high,	moderate	and	low),	we	observed	the	highest	risks	for	organ	sites	in	the	
head	region	that	received	the	highest	doses	of	scatter	radiation.	Although	these	data	
suggest	a	dose-response	relationship	in	hereditary	survivors,	given	the	number	of	organ	
sites	evaluated,	the	few	cases	for	some	of	the	sites,	and	the	number	of	variables	that	
could	have	affected	the	risk,	e.g.,	age	at	exposure,	current	age,	chemotherapy	in	addition	
to	radiation	and	smoking,	these	data	should	be	interpreted	cautiously.	Further,	it	was	
difficult	to	evaluate	the	heterogeneity	of	risk	in	this	cohort.	
Because	we	did	not	conduct	mutation	testing	on	all	of	the	survivors,	we	did	not	
know	whether	unilateral	patients	had	a	germline	mutation	that	was	less	penetrant.		
Therefore	we	relied	on	laterality	of	RB	and	mention	of	family	history	of	RB	in	the	medical	
record.		It	is	likely	that	some	unilateral	patients	survivors	may	have	been	misclassified	as	
non-hereditary,	due	to	unknown	family	history	of	RB	or	a	less	penetrant	form	of	a	
germline	RB1	mutation	(mosaicism).		This	would	have	biased	the	risk	in	the	non-
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hereditary	upward,	and	biased	the	ratio	of	risks	of	hereditary:	non-hereditary	towards	
the	null.	But	given	the	very	large	increase	in	risk	in	the	hereditary	patients,	the	
misclassification	would	likely	have	had	a	very	small	effect.	Interestingly,	when	we	
segregated	the	unilateral	patients	with	a	family	history	whom	we	had	classified	as	
hereditary,	their	second	cancer	risk	resembled	that	of	the	bilateral	patients.		
Although	we	collected	reports	of	subsequent	cancer	from	several	sources	
(medical	record	abstracts,	self-reports	and	death	certificates),	it	is	possible	that	we	may	
have	missed	some	cancers	that	are	non-fatal.		However,	given	the	large	ratios	of	
observed	to	expected	number	of	cancers	compared	with	the	general	population,	it	is	
possible	that	we	are	actually	underestimating	the	risks	of	these	cancers	(e.g.	thyroid,	
breast)	in	this	cohort.	A	comparison	of	the	incident	non-fatal	cancers	such	as	breast	and	
thyroid	with	deaths	for	these	two	cancers	in	hereditary	survivors	indicated	that	we	are	
ascertaining	incident	cancers	but	missing	non-fatal	cancer	deaths.	There	were	10	incident	
breast	cancers	whereas	there	were	only	2	deaths	from	breast	cancer,	and	there	were	2	
incident	thyroid	cancers	but	no	deaths	attributed	to	this	cause.		
This	analysis	establishes	that	one	in	three	hereditary	survivors	of	RB	is	at	risk	of	
developing	a	subsequent	cancer	by	age	50	years	likely	related	to	their	past	radiotherapy	
for	RB.	Sarcomas	and	melanomas	are	the	predominant	second	cancers.	However,	new	
increased	risks	were	noted	for	epithelial	cancers	in	this	cohort,	notably	those	of	the	lung,	
buccal	cavity	and	breast	as	well	as	leiomyosarcomas	of	the	uterus.	
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4.5	Public	health	message	
The	persistently	elevated	risk	of	subsequent	cancers	in	hereditary	but	not	non-
hereditary	survivors	points	to	the	need	for	life-long	surveillance	of	subsequent	cancers	in	
RB	patients	who	have	a	RB1	germline	mutation	and	for	those	treated	with	radiotherapy.		
4.6	Role	in	the	study	
Role:	I	initiated	the	study,	conducted	the	analysis	and	drafted	the	manuscript.	
Study	team:	Dr	Tarone	was	the	consulting	statistician;	Drs	Abramson	and	Seddon	were	
the	clinical	collaborators	and	provided	the	patients;	Dr	Stovall	provided	the	dose	data;	
Drs	Li,	Fraumeni	and	Tucker	were	the	senior	study	investigators	who	contributed	to	the	
interpretation	of	the	data.	My	contribution:	75%		
4.7	Publication	
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Chapter	5. Risk	of	Soft	tissue	sarcomas	by	histology	
Kleinerman	RA,	Tucker	MA,	Abramson	DH,	Seddon	JM,	Tarone	RE,	Fraumeni	JF,	
Jr.	Risk	of	soft	tissue	sarcomas	by	individual	subtype	in	survivors	of	hereditary	
retinoblastoma.	J	Natl	Cancer	Inst,	2007;99:24-31.	
5.1	Introduction	and	rationale	
Hereditary	retinoblastoma	survivors	have	a	high	risk	of	soft	tissue	sarcomas	(STS)	
compared	with	the	general	population	(Wong	et	al.,	1997),	but	the	risk	for	individual	
subtypes	of	STS	had	never	been	previously	estimated.		An	earlier	analysis	of	STS	risk	in	
relation	to	radiation	in	this	cohort	found	a	clear	dose-response	for	increasing	risk	of	STS	
with	increasing	dose	up	to	11-fold	for	doses	of	60	Gy	and	higher	(Wong	et	al.,	1997).		
However,	radiation	dose	was	only	available	on	a	subset	of	STS	patients	(31	out	of	44)	so	
we	did	not	calculate	the	risks	separately	by	individual	subtype	due	to	a	small	number	of	
affected	individuals.	In	addition,	STS	are	a	diverse	group	of	tumour	types,	and	we	wanted	
to	quantify	the	risks	by	subtype	to	investigate	whether	any	specific	subtype	was	
preferentially	elevated	after	RB	and	radiotherapy.		Identification	of	risk	of	specific	STS	
subtype(s)	and	age	at	occurrence	would	aid	in	the	surveillance	of	survivors	at	risk	for	
second	cancers.		
5.2	Methods	
STS	are	often	coded	according	to	the	site	or	organ	in	which	they	occur	(e.g.	
shoulder,	bladder,	colon,	uterus).		In	previous	analyses	in	this	cohort,	we	only	used	the	
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category	connective	tissue	(ICDO2	code	=	171)	to	define	STS.	For	example,	a	sarcoma	
could	be	diagnosed	in	a	uterus,	and	unless	the	histology	code	is	also	used,	it	would	be	
coded	as	a	uterine	cancer	rather	than	a	soft	tissue	sarcoma.	Therefore,	for	this	analysis,	
STS	were	coded	according	to	both	the	location	of	the	tumour	or	topography	and	its	
subtype	or	histology.		Using	this	approach	increased	the	number	of	soft	tissue	sarcomas	
available	for	analysis	(n=69).	This	was	far	larger	and	included	the	44	STS	reported	as	
connective	tissue	cancers.		The	69	STS	were	confirmed	by	pathology	report	(70%),	
autopsy	(4%),	other	hospital	records	(19%)	or	death	certificate	only	(7%)	and	were	coded	
according	to	ICDO-2	and	ICDO-3.	
This	analysis	was	restricted	to	the	963	hereditary	survivors	in	cohort	1,	because	
no	STS	were	diagnosed	in	any	non-hereditary	survivors.	Radiotherapy	was	treated	as	a	
yes/no	variable,	but	chemotherapy	was	scored	according	to	the	type	and	number	of	
individual	alkylating	agents	(0,	none;	1,	low;	2,	medium;	3	or	more,	high).		This	was	a	
modification	of	the	method	developed	by	Tucker	et	al	(Tucker	et	al.,	1987)	and	each	type	
of	chemotherapy	was	assigned	a	score	based	on	the	type	of	alkylating	agent	and	level	of	
toxicity.	The	individual	scores	were	then	summed	over	all	of	the	chemotherapy	courses	
to	calculate	an	alkylator	score	for	each	subject.	Almost	all	of	the	patients	who	received	
chemotherapy	also	received	radiotherapy.		The	small	number	of	survivors	who	received	
chemotherapy	alone	precluded	any	meaningful	analysis	of	this	group.	
The	expected	number	of	STS	by	subtype	was	based	on	rates	from	SEER.	Rates	
were	calculated	for	the	following	histologic	subtypes:	fibrosarcoma;	malignant	fibrous	
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histiocytoma;	liposarcoma;	leiomyosarcoma;	and	rhabdomyosarcoma;	STS	other	and	STS,	
not	otherwise	specified.	
The	statistical	analysis	included	calculation	of	standardised	incidence	ratios	for	
the	six	main	subtypes	of	STS,	stratified	by	type	of	treatment	(radiotherapy:	any,	none;	
chemotherapy	yes,	no;	and	alkylating	agent	score)	and	time	since	RB	diagnosis.	In	
addition,	we	calculated	cumulative	incidence	for	a	period	up	to	50	years	after	RB	
diagnosis	with	adjustment	for	competing	risk	of	death	due	to	other	causes.			Accrual	of	
person-years	at	risk	began	one	year	after	RB	diagnosis	and	ended	at	date	last	known	
alive,	date	of	death	or	December	31,	2000,	whichever	occurred	earliest.	
5.3	Main	Findings	
Most	of	the	survivors	were	treated	with	radiotherapy	(n=849)	and	45.1%	(n=383)	
of	these	survivors	also	received	chemotherapy.	We	identified	69	STS	in	68	survivors.	
Leiomyosarcoma	(LMS)	was	the	most	common	subtype	(33%),	followed	by	fibrosarcoma	
(19%),	malignant	fibrous	histiocytoma	(17%),	soft	tissue	tumours	and	sarcomas	NOS	
(15%),	rhabdomyosarcomas	(12%)	and	liposarcoma	(4.3%).	As	a	group,	the	STS	were	
more	often	diagnosed	in	the	head	and	face	(71%).		The	majority	of	LMS,	however,	were	
diagnosed	more	often	outside	the	radiation	field	in	contrast	to	the	other	STS	subtypes.	
5.3.1	Treatment	
SIRs	were	significantly	elevated	for	all	of	the	STS	subtypes	with	the	highest	SIRs	
noted	for	leiomyosarcomas	(SIR=390)	and	fibrosarcomas	(SIR=398).	Most	of	the	STS	were	
diagnosed	in	irradiated	survivors;	3	STS	developed	in	survivors	who	had	not	been	
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irradiated.		SIRs	were	also	elevated	similarly	in	irradiated	patients	who	did	and	did	not	
receive	chemotherapy.	The	excess	absolute	risks	were	similar	for	those	who	also	
received	chemotherapy	(EAR=33.5)	compared	with	those	who	did	not	receive	
chemotherapy	(EAR=27.7),	with	the	exception	of	LMS	that	had	higher	EARs	associated	
with	chemotherapy	and	rhabdomyosarcoma	that	only	occurred	in	those	without	
chemotherapy.		
We	did	not	observe	a	trend	of	increasing	risk	for	STS	(all	types	combined)	with	
increasing	alkylator	score.	The	most	common	chemotherapy	agent	used	in	this	
population	was	Triethylenemelamine	(TEM).			
5.3.2	Latency	
The	SIRs	were	highest	in	the	first	10	years	after	RB	diagnosis	and	continued	to	be	
diagnosed	up	to	30	years	and	later	for	all	subtypes	except	LMS	and	liposarcomas.	LMS	
were	not	diagnosed	until	20	years	after	RB	diagnosis	and	most	occurred	30	years	and	
later	(Table	5.1).		
5.3.3	Gender	
Risks	for	STS	did	not	differ	by	gender,	however,	the	location	of	the	LMS	did	differ	
by	sex	with	the	majority	of	the	LMS	diagnosed	in	the	head	in	males	(64%)	and	in	the	
uterus	in	females	(58%).	
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Table	5.1	Risk	of	soft	tissue	sarcoma	in	1-year	survivors	of	hereditary	retinoblastoma	by	time	since	diagnosis	of	retinoblastoma	
	 Number	of	years	(yrs)	since	retinoblastoma	diagnosis	
	 1	-	9	yrs	 10	-	19	yrs	 20	-	29	yrs	 30+	yrs	
No.	of	subjects	starting	each	
interval	 963	 791	 658		 465		
No.	of	person-years	 7649	 7381	 5691	 4573	
Histology	and	ICD-O	Classification	 O
	
*	 SIR,	95%CI†	 	 O	 SIR,	95%CI	 O	 	
SIR,	
95%CI	 O	 	 SIR,	95%CI	 	
Soft	tissue	tumors	and	sarcomas,	
NOS		 4	 229	(62-585)	 2	 85	(9.5-307)	 1	 34	(0.4-192)	 3	 88	(18-258)	
Fibrosarcoma		 4	
598	(161-
1531)	 4	 387	(104-904)	 2	 250	(28-904)	 3	 393	(79-1147)	
Malignant	Fibrous	Histiocytoma		 2	 488	(55-1760)	 4	 209	(56-534)	 1	 24	(0.3-136)	 5	 90	(29-210)	
Liposarcoma		 0	 0	(0-5038)	 2	 836	(94-3019)	 0	 0	(0-467)	 1	 51	(0.7-282)	
Leiomyosarcoma		 0	 0	(0-3468)	 1	
213	(2.8-
1187)	 4	 336	(90-861)	
1
8	 435	(258-687)	
Rhabdomyosarcoma		 4	 340	(92-871)	 3	 286	(57-835)	 0	 0	(0.0-908)	 1	 428	(5.6-2380)	
Total	 14	 335	(183-562)	 16	 227	(129-368)	 8	 79	(34-155)	
3
1	 193	(131-274)	
	 		 		 		 		
*observed	
†Standardized	incidence	ratio	and	95%	confidence	interval	
	 81	
5.4	Significance	
This	was	the	first	study	of	RB	survivors	with	sufficient	long-term	follow	up	to	
identify	increased	risks	of	STS	by	subtype	(Kleinerman	et	al.,	2007).	The	most	common	
type	and	highest	risks	were	noted	for	LMS.	Although	LMS	were	diagnosed	in	irradiated	
survivors,	the	majority	of	LMS	was	diagnosed	outside	the	radiation	field.	Higher	risks	for	
LMS	were	noted	for	those	who	also	received	chemotherapy,	and	LMS	was	not	diagnosed	
until	age	20	years	and	the	majority	occurred	after	age	30.		The	location	of	the	LMS	also	
differed	by	gender	with	males	having	LMS	diagnosed	in	the	head	and	females	diagnosed	
with	LMS	of	the	uterus.	
The	novelty	of	this	study	was	the	analysis	of	the	STS	by	histologic	sub-type.	We	
created	rates	from	the	general	population	based	on	the	main	STS	subtypes.	This	
permitted	us	to	report	risks	by	individual	subtypes	for	this	population.	Interestingly,	we	
found	variation	by	subtype	in	time	to	appearance	after	RB	diagnosis	as	well	variation	in	
the	location	of	the	STS	in	relation	to	the	radiation	field.		This	has	important	implications	
for	screening	survivors	in	relation	to	when	they	should	be	screened	for	specific	STS.		
This	analysis	also	moved	beyond	the	previous	analyses	by	attempting	to	take	into	
account	the	influence	of	alkylating	agents	on	the	risk	of	STS.	Most	of	the	previous	
analyses	of	these	data	(Eng	et	al.,	1993,	Wong	et	al.,	1997)	focused	on	the	effect	of	
radiation	on	second	cancers	and	did	not	take	into	account	the	influence	of	chemotherapy	
that	was	given	to	almost	half	of	those	patients	who	were	irradiated	in	the	cohort.	
Although	this	analysis	did	not	indicate	an	increasing	risk	with	increasing	alkylating	agent	
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score	for	all	STS	combined,	we	did	find	a	heightened	risk	for	LMS	with	chemotherapy	
combined	with	radiation.		
This	was	also	the	first	analysis	to	note	the	different	locations	of	the	LMS	by	
gender.	Based	on	these	findings,	female	survivors	30	years	and	older	need	to	be	aware	of	
the	possibility	of	LMS	of	the	uterus.	This	finding	prompted	another	analysis	in	these	data	
focused	on	the	risk	of	uterine	LMS	(Francis	et	al.,	2012)	that	suggested	that	female	
survivors	may	want	to	consider	undergo	hysterectomies	at	the	end	of	childbearing	in	
order	to	avoid	this	possible	second	cancer.	
In	an	accompanying	editorial	to	this	analysis	(Meadows,	2007)	Meadows	noted	
“The	report	by	Kleinerman	et	al	in	this	issue	of	the	Journal	contains	new	information	that	
is	important	for	clinicians	who	follow	retinoblastoma	survivors.”...”Improved	treatment	
can	be	expected	to	reduce	the	incidence	of	soft	tissue	(and	bone)	sarcomas	associated	
with	radiation.	The	importance	of	this	report	lies	in	its	emphasis	on	leiomyosarcoma,	a	
tumour	that	occurs	in	RB1	gene	carriers	whether	or	not	they	were	treated	with	radiation	
and	that	can	be	expected	to	continue	to	occur	in	older	survivors,	who	will	require	more	
careful	follow-up.”	
5.5	Public	Health	Message	
Survivors	with	hereditary	RB	have	a	genetic	predisposition	to	soft	tissue	
sarcomas.	Long-term	surveillance	for	sarcomas	is	warranted	for	these	survivors,	because	
leiomyosarcomas,	which	are	the	most	common	soft	tissue	sarcomas	in	survivors,	mainly	
occur	30	years	after	RB	diagnosis.		
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5.6	Role	in	study	
Role:	I	initiated	the	idea	for	the	study,	conducted	the	analysis	and	drafted	the	
manuscript.	Study	team:	Dr	Tarone	was	the	consulting	statistician,	Drs	Abramson	and	
Seddon	were	the	clinical	collaborators	and	provided	the	patients;	Drs	Tucker	and	
Fraumeni	were	the	senior	study	investigators.	My	contribution:	80%	
5.7	Publication	
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Chapter	6. Mortality	of	second	cancers	
Yu	CL,	Tucker	MA,	Abramson	DH,	Furukawa	K,	Seddon	JM,	Stovall	M,	Fraumeni	
JF	Jr,	Kleinerman	RA.		Cause-specific	mortality	in	long-term	survivors	of	retinoblastoma.	
J	Natl	Cancer	Inst,	2009:101:581-91.		
6.1	Introduction	and	rationale		
	 Although	the	risk	of	dying	from	second	malignancies	has	been	established	
in	this	cohort	(Eng	et	al.,	1993)	and	other	sources	(Acquaviva	et	al.,	2006,	Fletcher	et	al.,	
2004)	mortality	data	was	limited	among	long-term	survivors	of	RB	treated	with	radiation.		
New	information	on	mortality	could	indicate	additional	risks	for	these	survivors	and	
provide	data	for	follow-up	guidelines.	
6.2	Methods	
We	investigated	cause-specific	mortality	in	cohort	1	(n=1599)	diagnosed	1914-
1984	and	cohort	2	(n=255)	who	were	treated	more	recently	from	1985-1996	at	one	
institution.		The	combined	cohort	was	comprised	of	1854	one-year	survivors	of	RB.	This	
analysis	excluded	3	subjects	from	cohort	1	that	had	been	included	in	earlier	analyses,	due	
to	two	survivors	with	resided	outside	the	US	and	one	subject	who	was	subsequently	
found	to	not	have	RB.	For	cohort	2,	we	included	two	subjects	in	this	analysis	who	were	
subsequently	excluded	from	later	analyses	due	to	being	consultation	only	patients.	
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Survivors	were	classified	as	either	hereditary	(bilateral	RB	or	unilateral	with	family	
history	of	RB)	or	non-hereditary	(unilateral	with	no	history	of	RB).	RB1	mutation	testing	
was	not	available	to	verify	which	patients	had	a	germline	mutation.		
Various	tracing	sources	were	used	to	determine	the	vital	status	of	the	cohorts,	
and	the	cohorts	were	submitted	to	the	NDI	in	2005.	The	most	recent	date	of	death	
available	at	that	time	of	this	study	was	2003.	The	NDI	provided	coded	causes	of	death	
according	to	International	Classification	of	Diseases	Eighth	revision	(ICD-8),	in	which	
tumours	are	coded	according	to	organ	site	rather	than	histology.		All	reported	causes	of	
death	in	the	cohort	prior	to	this	search	were	converted	to	ICD-8	to	be	compatible	for	
analysis.	
Person-years	began	one-year	after	RB	diagnosis	and	ended	on	the	date	the	
survivor	was	last	known	alive,	date	of	death	or	end	of	follow-up	(December	31,	2003),	
whichever	occurred	earliest.		Survivors	last	known	to	be	alive	as	of	January	1,	1979,	lived	
in	the	U.S.	and	not	found	in	the	NDI	were	presumed	to	be	alive	as	of	December.	31,	
2003.		There	were	1380	(74%)	survivors	alive,	423	(22.8%)	had	died	and	51	(2.8%	)	were	
lost	to	follow-up.	For	survivors	last	known	to	be	alive	since	1979	when	the	NDI	started,	
we	made	the	assumption	that	if	a	survivor	was	not	matched	with	the	NDI,	then	we	could	
consider	them	alive	as	of	the	date	of	NDI	linkage.		
	 We	estimated	the	relative	risk	for	each	cause	of	death	compared	with	
death	in	the	general	population	by	calculating	a	SMR	and	exact	Poisson	confidence	
intervals.		The	expected	number	of	deaths	was	calculated	by	applying	the	US	mortality	
rates	from	1925	onwards	(by	5-year	age,	5	calendar	year,	and	sex	specific	categories)	to	
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the	person-years	at	risk	calculated	for	the	RB	cohort.	To	measure	the	overall	burden	of	
disease,	we	also	calculated	EARs.		In	addition,	we	compared	SMRs	for	all	survivors	who	
were	at	least	25	years	of	age	with	SMRs	from	a	UK	study	by	Fletcher	et	al.	(Fletcher	et	al.,	
2004)	using	the	chi-square	test	of	homogeneity.			
In	order	to	investigate	the	influence	of	multiple	factors	on	the	SMRs,	we	
estimated	the	relative	rates	of	each	factor	by	fitting	Poisson	regression	models.	The	
likelihood	ratio	test	was	used	to	test	the	statistical	significance	of	each	factor.		The	main	
factors	of	interest	were	hereditary	status,	age	at	RB	diagnosis	(≤12	months,	>12	months),	
attained	age,	(<25	yrs	and	≥25	yrs),	time	since	RB	diagnosis	by	decade,	and	calendar	year	
of	RB	diagnosis	(<1960	and	≥1960).		Cut	points	were	determined	a	priori	by	the	changes	
in	radiotherapy	treatment	in	1960	and	past	study	that	suggested	greater	sensitivity	to	
radiation	for	children	≤12	months	of	age	(Moll	et	al.,	2001).	We	tested	the	interaction	of	
hereditary	status	and	radiotherapy	using	a	product	term.	
Cause-specific	cumulative	mortality	was	calculated	by	treating	other	causes	as	
competing	risks	using	the	R	statistical	software	(Gray,	1988).	
6.3	Main	Findings	
The	median	age	of	the	combined	cohorts	at	the	end	of	follow-up	was	30	years	
(range	1-79	years).		The	median	duration	of	follow	up	was	similar	for	the	hereditary	and	
non-hereditary	survivors	(28.5	yrs	and	29.6	yrs,	respectively).		At	the	end	of	follow-up,	
there	were	423	deaths	(346	in	cohort	1	and	77	in	cohort	2).		This	analysis	identified	70	
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additional	deaths	in	cohort	1	since	the	last	follow-up,	and	this	was	the	first	mortality	
analysis	in	cohort	2.		
We	observed	151	deaths	due	to	second	malignant	neoplasms	other	than	RB	in	
1092	hereditary	survivors	(SMR=35,	95%CI	30-41)	compared	with	12	deaths	in	762	non-
hereditary	survivors	(SMR=2.5,	95%,	95%CI	1.3-4.4)	(see	Table	6.1).	
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Table	6.1	Causes	of	death	other	than	retinoblastoma	in	1-Year	survivors	by	hereditary	status	
		 All	 Hereditary	 Nonhereditary	
No.	of	persons	followed	up	 1854	 1092	 762	
Person-years	 49924	 28250	 21674	
Cause	of	Death*	(ICD-8	code)	 O	 SMR	(95%	CI)	 EAR	 O	 SMR	(95%	CI)	 EAR	 O	 SMR	(95%	CI)	 EAR	
Malignant	and	benign	neoplasms	other	
than	Rb†	
172	 19	(16,	22)	 32.6	 160	 37	(31,	43)	 55.1	 12	 2.5	(1.3,	4.3)	 3.3	
Malignant	neoplasms	other	than	Rb	 163	 18	(15,	21)	 30.8	 151	 35	(30,	41)	 51.9	 12	 2.5	(1.3,	4.4)	 3.3	
Bone	(170)	 56	 332	(251,	431)	 11.2	 56	 595	(449,	773)	 19.8	 0	 0	(0,	49)	 0.0	
Connective	tissue	(171)	 31	 175	(119,	248)	 6.2	 31	 329	(223,	467)	 10.9	 0	 0	(0,	44)	 0.0	
Melanoma	(172)	 13	 44	(24,	76)	 2.5	 13	 89	(47,	151)	 4.5	 0	 0	(0,	25)	 -0.1	
Brain	and	other	parts	of	nervous	system	
(191-192)	
12	 16	(8.4,	28)	 2.3	 10	 25	(12,	46)	 3.4	 2	 5.9	(0.7,	21)	 0.8	
Brain	(191)	 8	 13	(5.5,	25)	 1.5	 6	 18	(6.5,	39)	 2.0	 2	 6.7	(0.8,	24)	 0.8	
Other	parts	of	nervous	system	(192)
‡
	 4	 36	(9.6,	91)	 0.8	 4	 61	(16,	155)	 1.4	 0	 0	(0,	80)	 0.0	
Lung	and	trachea	(162)	 8	 4.9	(2.1,	9.7)	 1.3	 8	 12	(5.3,	24)	 2.6	 0	 0	(0,	3.8)	 -0.5	
Corpus	uteri	(182)§	 6	 81	(30,	177)	 1.2	 5	 154	(50,	359)	 1.8	 1	 24	(0.3,	134)	 0.4	
Nasal	cavities	(160)	 5	 392	(126,	914)	 1.0	 5	 790	(254,	
1843)	
1.8	 0	 0	(0,	570)	 0.0	
Breast	(174)	 5	 5.1	(1.6,	12)	 0.8	 2	 4.4	(0.5,	16)	 0.5	 3	 5.7	(1.2,	17)	 1.1	
Buccal	cavity	and	pharynx	(140-149)**	 2	 15	(1.7,	55)	 0.4	 2	 34	(3.8,	123)	 0.7	 0	 0	(0,	51)	 -0.03	
Leukemia	(204-207)
††
	 2	 1.9	(0.2,	6.9)	 0.2	 1	 1.7	(0.02,	9.5)	 0.1	 1	 2.2	(0.03,	12)	 0.2	
Thyroid	(193)	 1	 55	(0.7,	305)	 0.2	 0	 0	(0,	436)	 0.0	 1	 102	(1.3,	568)	 0.5	
Bladder	(188)	 1	 15	(0.2,	85)	 0.2	 1	 40	(0.5,	224)	 0.3	 0	 0	(0,	90)	 0.0	
Benign	tumors	(210-239)
‡‡
	 9	 38	(17,	73)	 1.8	 9	 72	(33,	137)	 3.1	 0	 0	(0,	33)	 -0.1	
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Table	6.1	Continued	
	 All	 Hereditary	 Nonhereditary	
No.	of	persons	followed	up	 1854	 1092	 762	
Person-years	 49924	 28250	 21674	
Cause	of	Death*	(ICD-8	code)	 O	 SMR	
(95%	CI)	
EAR	 O	 SMR	(95%	
CI)	
EAR	 O	 SMR	
(95%	CI)	
EAR	
Other	known	causes	of	death	 39	 1.0	(0.7,	
1.3)	
-0.4	 19	 0.9	(0.5,	
1.4)	
-0.9	 20	 1.0	(0.6,	
1.6)	
0.2	
Infections	(000-139)	 3	 1.1	(0.2,	
3.3)	
0.1	 1	 0.7	(0.01,	
3.9)	
-0.1	 2	 1.7	(0.2,	
6.0)	
0.4	
Endocrine	and	Metabolic	
(240-279)	
2	 1.5	(0.2,	
5.4)	
	0.1	 	1		 1.5	(0.02,	
8.4)		
0.1	 1	 1.5	(0.02,	
8.3)		
0.2	
Mental	disorders	(290-315)	 3	 4.7	(0.9,	
14)	
0.5	 0	 0	(0,	11)	 -0.1	 3	 9.7	(2.0,	
28)	
1.2	
Neurologic	(320-389)	 2	 1.5	(0.2,	
5.5)	
0.1	 2	 2.9	(0.3,	
10)	
0.5	 0	 0	(0,	6.0)	 -0.3	
Circulatory	(390-458)	 7	
1.0	(0.4,	
2.0)	
-
0.05	
4	
1.3	(0.3,	
3.2)	
0.3	 3	
0.7	(0.2,	
2.2)	
-0.5	
Arteriosclerotic	heart	disease	
(410-414)	
4	
1.1	(0.3,	
2.8)	
0.1	 3	
2.0	(0.4,	
5.7)	
0.5	 1	
0.5	(0.01,	
2.6)	
-0.5	
Cerebrovascular	accidents	
(430-438)	
1	
1.0	(0.01,	
5.3)	
-
0.01	
1	
2.1	(0.03,	
11)	
0.2	 0	 0	(0,	6.5)	 -0.3	
Respiratory	(460-519)	 2	
1.1	(0.1,	
3.9)	
0.03	 2	
2.3	(0.3,	
8.2)	
0.4	 0	 0	(0,	3.7)	 -0.5	
Digestive	system	(520-579)	 5	
2.7	(0.9,	
6.2)	
0.6	 3	
3.3	(0.7,	
9.5)	
0.7	 2	
2.1	(0.2,	
7.6)	
0.5	
External	causes	(800-998)	 15	
0.7	(0.4,	
1.1)	
-1.6	 6	
0.5	(0.2,	
1.0)	
-2.4	 9	
0.9	(0.4,	
1.7)	
-0.5	
Ill-defined condition (796) 10 
11.4 
(5.5, 21) 
1.8 6 
13 (4.7, 
28) 
2.0 4 
9.9 (2.7, 
25) 
1.7 
*Death	certificate	not	available	for	13	hereditary	and	3	non-hereditary	RB	survivors.	
†Cancer	sites	not	listed	for	herediitary	RB	include	retroperitoneal	(2),	colon	(1),	non-melanoma	skin	
cancer	(2),	ovary	(1),	kidney	(1),	pineal	gland	(1),	lymphoid	tissue	(1),	cancer,	NOS	(7);	and	for	non-
hereditary,	cancer,	NOS	(4).	
‡
Neuroblastoma	(4)	
§Hereditary:	LMS	(3),	carcincoma	(1),	Mullerian	mixed	tumor	(1);	non-hereditary:	cancer	of	corpus	uteri	
**Nasopharynx	(2)	
††
Hereditary:	Acute	lymphocytic	leukemia	(1)	and	non-hereditary:	acute	myeloid	leukemia	(1)	
‡‡
Benign	tumors:	meningioma	of	the	spine	(1),	pituatary	gland	andcraniopharyngeal	duct	(1)	and	brain	
neoplasoms,	NOS	(7).	
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The	most	common	subsequent	malignant	neoplasms	in	hereditary	survivors	were	
sarcomas	of	bone	and	connective	tissue,	melanoma	and	cancers	of	the	brain	and	other	
central	nervous	system	tumours.	For	the	non-hereditary	survivors,	elevated	mortality	
was	noted	for	only	cancer	of	the	breast	and	thyroid.		Among	the	non-hereditary	
survivors,	the	SMRs	were	only	significantly	elevated	for	those	who	received	radiotherapy	
for	RB	(6	deaths,	SMR=7.3,	95%CI	2.7-15.8)	but	not	for	those	who	did	not	receive	
radiotherapy	(6	deaths,	SMR=1.5,	95%CI	0.6-3.3).	We	did	not	observe	elevated	mortality	
due	to	non-cancer	causes	in	hereditary	nor	non–hereditary	survivors.	
The	SMRs	differed	significantly	by	attained	age	for	the	hereditary	survivors,	with	
higher	SMR	for	<25	yrs	vs.	≥	25	yrs	(SMR=76,	95%CI	61-95	and	SMR=22,	95%CI	17-28)	
(Table	3).		Sarcomas	accounted	for	76.5%	of	deaths	prior	to	age	25,	whereas,	they	
accounted	for	only	35.7%	of	deaths	25	years	and	older.		Excess	mortality	in	the	older	age	
group	was	mainly	attributed	to	deaths	from	melanoma,	lung	cancer,	uterine	cancer	and	
digestive	organs.	
Similar	to	the	second	cancer	incidence	data,	radiation	conferred	a	3.4	times	
higher	risk	of	death	from	all	second	cancers	compared	with	the	SMR	for	all	second	
cancers	in	non-irradiated	hereditary	patients.	Among	the	hereditary	survivors	who	died	
of	a	second	cancer,	the	median	age	at	death	for	the	140	irradiated	survivors	was	younger	
than	the	median	age	at	death	for	the	11	non-irradiated	survivors	(20.5	years,	range	1-67	
years	versus	44	years,	range	10-64	years).		In	addition,	hereditary	survivors	irradiated	≤12	
months	of	age	(SMR=59,	95%CI	48-73)	were	2.2	times	more	likely	to	die	of	a	second	
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cancer	than	those	survivors	who	were	irradiated	>12	months	of	age	(SMR=27,	95%CI	20-
35).			
Comparison	of	SMRs	for	all	second	cancers	by	gender	did	not	reveal	any	
statistically	significant	differences	(Males,	SMR=38,	95%CI	29-48	and	females,	SMR=	46,	
95%	CI	36-57).			However,	the	risk	of	death	from	cancer	of	the	brain	and	other	parts	of	
the	nervous	system	was	greater	in	females	compared	with	males	(SMR	for	females=67,	
95%CI	30-127,	9	cancers	compared	with	SMR	for	males=	5.1,	95%CI	0.07-28,	1	cancer;	
P=0.001).		
Radiotherapy	for	RB	was	related	to	increased	RRs	for	second	cancers	among	both	
hereditary	and	non-hereditary	survivors.	We	observed	higher	RR	for	all	second	cancers	
combined	in	non-hereditary	patients	(RR=7.19,	95%CI	2.2-23	based	on	6	second	cancers)	
compared	with	hereditary	patients	(RR=2.46,	95%	CI	1.4-4.8	based	on	140	second	
cancers).		Table	6.2	shows	the	results	of	a	multivariable	Poisson	model	that	evaluated	the	
relative	rates	of	death	from	second	cancers	in	relation	to	possible	modifiers	of	risk	in	
hereditary	and	non-hereditary	survivors.	
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Table	6.2.	Multivariate	Poisson	regression	model	of	relative	rate	of	mortality	from	subsequent	
malignant	neoplasms	in	1-year	survivors	of	retinoblastoma,	by	hereditary	status	
	
	 Hereditary	 Non-hereditary	
Risk	factor	 O	 RR	(95%CI)	 P*	 O	 RR	(95%	CI)	 P*	
Radiation	 	 	 0.001	 	 	 0.002	
No	 11	 1.0	(referent)	 	 6	 1.0	(referent)	 	
Yes	 140	 2.46	(1.39,	4.84)	 	 6	 7.19	(2.21,	23.37)	 	
Sex	 	 	 0.03	 	 	 0.42	
Male	 67	 1.0	(referent)	 	 4	 1.0	(referent)	 	
Female	 84	 1.41	(1.03,	1.95)	 	 8	 1.63	(0.51,	6.21)	 	
Age	at	Rb	diagnosis	 	 	 0.06	 	 	 0.63	
0-12	months	 95	 1.37	(0.99,	1.93)	 	 3	 1.40	(0.31,	4.79)	 	
>12	months	 56	 1.0	(referent)	 	 9	 1.0	(referent)	 	
Calendar	year	of	RB	diagnosis	 0.05	 	 0.10	
1914-1959	 78	 1.44	(1.00,	2.05)	 	 9	 3.85	(0.77,	21.02)	 	
1960+	 73	 1.0	(referent)	 	 3	 1.0	(referent)	 	
Latency,	years	 	 	 <0.001	 	 	 0.05	
1-9	 19	 1.0	(referent)	 	 1	 1.0	(referent)	 	
10-19	 52	 3.40	(2.05,	5.90)	 	 3	 3.28	(0.41,	66.62)	 	
20-29	 25	 2.01	(0.91,	4.22)	 	 2	 0.94	(0.02,	40.50)	 	
30-39	 30	 3.59	(1.33,	9.56)	 	 0	 NA	 	
40+	 25	 5.82	(2.09,	15.95)	 	 6	 2.79	(0.07,	170.38)	 	
Attained	age	 	 	 0.76	 	 	 0.37	
1-24	years	 81	 1.0	(referent)	 	 4	 1.0	(referent)	 	
25+	years	 70	 1.13	(0.52,	1.56)	 	 8	 4.16	(0.22,	74.39)	 	
Abbreviations:	Rb,	retinoblastoma;	O,	observed;	RR,	relative	rate;	CI,	confidence	interval;	NA,	not	applicable	
	
*P-value	from	likelihood	ratio	test	
	
We	evaluated	the	interaction	between	hereditary	status	and	radiotherapy	but	
found	that	the	interaction	between	these	two	variables	was	not	statistically	significant	
(Table	6.3).	
Table	6.3.	Risk	of	mortality	from	second	cancers	in	retinoblastoma	patients	by	
radiotherapy	and	hereditary	status	
Type	of	
retinoblastoma	 No	Radiotherapy	 Radiotherapy	
Hereditary	 RR=7.12			(95%CI	2.7-21)	 RR=17.9	(95%CI	8.6-46)	
Non-hereditary	 RR=1.00	 RR=7.20	(95%CI	2.3-23)	
Likelihood	ratio	test	for	interaction	P=0.12	
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The	cumulative	mortality	from	second	cancers	at	50	years	after	RB	after	
adjustment	for	competing	risk	of	death	from	other	causes	differed	for	hereditary	and	
non-hereditary	survivors	(25.5%,	95%	CI	21-30	and	1.0%,	95%CI	0.2-1.8).		Further	
investigation	of	the	cumulative	mortality	among	hereditary	survivors	revealed	
differences	by	radiotherapy,	but	the	confidence	intervals	overlapped	(radiotherapy,	
26.8%,	95%CI	22-32	and	no	radiotherapy,	17.2%,	95%	CI	5.4-29).	
6.4	Significance	
Compared	with	the	general	population,	we	demonstrated	that	hereditary	RB	
survivors	had	increased	risks	of	deaths	from	second	cancers	(Yu	et	al.,	2009).	These	risks	
greatly	exceeded	those	from	RB	and	from	other	non-cancer	causes.	The	most	common	
causes	of	death	were	from	sarcomas,	melanomas,	and	cancers	of	the	brain	and	other	
parts	of	the	nervous	system.	Deaths	attributable	to	second	cancers	occurred	beyond	40	
years	after	RB	diagnosis.		The	study	revealed	for	the	first	time	a	previously	unreported	
increased	risk	of	death	due	to	uterine	corpus	cancer	(mainly	sarcomas)	and	confirmed	
the	elevated	risk	of	lung	cancer	that	we	reported	previously	(Kleinerman	et	al.,	2000)	
(see	Chapter	3).		Among	both	hereditary	and	non-hereditary	survivors,	the	relative	rates	
of	mortality	from	second	cancers	were	higher	in	those	treated	previously	with	
radiotherapy	compared	with	those	who	had	not	received	radiation.		It	should	be	noted	
that	RB	survivors	were	not	at	increased	risk	of	death	from	non-cancer	causes	compared	
with	the	general	population.		
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This	mortality	analysis	differed	from	the	previous	mortality	study	in	this	cohort	
(Eng	et	al.,	1993)	by	increasing	the	number	of	person	years	with	an	additional	13	years	of	
follow	up	as	well	as	including	survivors	from	cohort	2	(n=255).	The	previous	mortality	
analysis	had	classified	survivors	according	to	laterality	whereas	the	current	analysis	used	
hereditary	status.		This	had	the	effect	of	combining	unilateral	patients	with	a	family	
history	of	RB	who	presumably	had	a	germline	mutation	with	bilateral	survivors	in	the	
hereditary	group.		This	new	analysis	also	stratified	the	SMRs	by	attained	age	and	
treatment-related	variables,	evaluated	the	effects	of	possible	risk	factors	on	the	risk	of	
mortality	from	second	cancers	by	hereditary	status,	modelled	the	interaction	between	
radiotherapy	and	hereditary	status	and	investigated	risks	by	gender.		
Although	these	data	indicate	an	increased	risk	of	dying	from	a	second	cancer	
among	those	survivors	who	were	treated	with	radiation,	regardless	of	hereditary	status,	
the	majority	of	the	second	cancer	deaths	occurred	in	the	hereditary	patients	who	were	
treated	with	radiation.		Interestingly,	the	relative	rate	of	dying	of	a	second	cancer	related	
to	radiotherapy	was	lower	among	hereditary	survivors	compared	with	non-hereditary	
survivors.	This	could	reflect	a	higher	background	rate	for	second	cancers	in	hereditary	
survivors	due	to	their	genetic	susceptibility	to	second	cancers,	which	would	result	in	a	
lower	relative	rate	of	second	cancers	due	to	radiotherapy.	The	interaction	between	
hereditary	status	and	radiation	did	not	reach	statistical	significance.				
Among	the	hereditary	survivors	the	other	risk	factors	in	addition	to	radiation	that	
were	statistically	significantly	associated	with	dying	from	a	second	cancer	were	female	
gender,	and	increasing	risk	with	increasing	time	since	RB	diagnosis	(latency).	
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Overall,	the	cumulative	mortality	risk	of	dying	from	a	second	cancer	indicated	a	
risk	of	1	in	4	hereditary	survivors	dying	50	years	after	RB	diagnosis	compared	with	only		1	
in	100	non-hereditary	survivors	over	the	same	time	period.	
One	notable	limitation	is	that	cause	of	death	recorded	on	death	certificates	may	
be	inaccurate	in	some	cases.		When	we	investigated	the	nine	causes	of	death	attributed	
to	benign	tumours,	we	found	that	four	of	these	persons	who	had	died	had	been	
diagnosed	with	a	soft	tissue	sarcoma	of	the	cranial	or	facial	area,	one	had	a	malignant	
glioma,	and	another	had	a	sebaceous	carcinoma	of	the	eyelid.	Additionally,	mortality	is	
not	a	good	measure	of	non-fatal	cancers	such	as	breast	or	thyroid	cancer.		
Although	we	had	data	up	to	60	years	after	RB	diagnosis,	the	number	of	survivors	
followed	50	years	and	more	was	only	72	in	both	the	hereditary	and	non-hereditary	
groups.	Age	50	is	when	usually	when	epithelial	cancers	start	to	increase	and	although	
SMRs	for	many	epithelial	cancers	were	elevated,	the	number	of	observed	cancer	deaths	
was	small	for	some	sites.			We	were	not	able	to	reliably	estimate	risks	of	dying	from	
specific	epithelial	causes,	such	as	bladder	cancer,	which	had	been	reported	by	a	UK	study	
(Fletcher	et	al.,	2004)	and	Dutch	study	(Marees	et	al.,	2010).		
Interestingly,	there	was	a	substantial	increase	in	the	EARs	over	time	in	hereditary	
patients	from	EAR=21	at	1-9	years	after	RB	up	to	EAR=132	at	³40	years	and	more	after	
RB	diagnosis,	indicating	that	the	burden	of	cancer	deaths	increased	with	time	since	
diagnosis.	For	the	non-hereditary	patients,	the	EARs	increased	from	EAR=1.1	at	1-9	years	
to	EAR=18	at	³40	years.	
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Although	it	was	not	the	focus	of	this	paper,	it	is	of	interest	to	follow	up	the	cohort	
with	another	mortality	analysis	as	the	cohort	ages	in	order	to	learn	more	about	the	risk	
of	non-cancer	causes	that	have	been	linked	to	radiation	such	as	heart	disease	(Aleman	et	
al.,	2014).	
These	mortality	data	combined	with	the	incidence	data	provide	information	
about	risks	of	second	cancers	that	can	help	guide	health	care	providers	and	hereditary	
survivors	as	to	what	risks	they	need	to	be	aware	of	as	they	age	as	well	as	inform	
development	of	screening	programs	for	the	early	detection	and	treatment	of	some	
cancers	
6.5	Public	Health	Message	
Hereditary	RB	survivors	are	more	likely	to	die	of	a	second	cancer	than	RB.		These	
survivors	should	be	followed	for	their	lifetime	for	the	possible	development	of	second	
cancers	and	encouraged	to	be	aware	of	these	risks	to	permit	early	identification	of	
second	cancers.		Non-hereditary	survivors	are	at	no	greater	risk	of	dying	from	a	second	
cancer	than	the	general	population.	
6.6	Role	in	study	
Role:	I	initiated	the	idea	for	the	study.	Study	team:	Dr	Yu	analysed	the	study	and	
drafted	the	manuscript.	Dr	Yu	was	a	post-doctoral	fellow	whom	I	mentored.	Dr	Furukawa	
provided	statistical	consultation	to	Dr	Yu.	Drs	Abramson	and	Seddon	were	the	clinical	
collaborators;	Dr	Stovall	provided	dose	data;	and	Drs	Tucker	and	Fraumeni	were	the	
senior	study	investigators.	My	contribution:	60%.		
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6.7	Publication	
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Chapter	7. Family	history	of	retinoblastoma	
Kleinerman	RA,	Yu	CL,	Little	MP,	Li	Y,	Abramson	DH,	Seddon	JM,	Tucker	MA.	
Variation	of	second	cancer	risk	by	family	history	among	long-term	survivors	of	
retinoblastoma.	J	Clin	Oncol,	2012;30:950-957.	
7.1	Introduction	and	rationale	
	 The	increased	risk	of	second	cancers	diagnosed	in	hereditary	
retinoblastoma	patients	is	well	established,	but	studies	have	not	previously	assessed	how	
this	risk	varies	according	to	whether	a	germline	RB1	mutation	was	inherited	from	a	
parent	or	occurred	de	novo.		This	information	could	provide	an	insight	into	biological	
mechanisms	and	influence	surveillance	recommendations	for	hereditary	survivors	of	RB.	
Although	this	cohort	does	not	have	mutation	testing	data	for	germline	RB1	mutations,	
we	estimated	the	risk	of	second	cancers	according	to	laterality	and	family	history	as	
surrogate	measures	for	mutation	status	(inherited	or	de	novo).	Survivors	are	inferred	to	
have	a	germline	mutation	based	on	the	presence	of	tumours	in	both	eyes	(bilateral)	or	in	
one	eye	(unilateral)	with	a	family	history	of	RB.	
The	question	that	we	asked	was:		Are	RB	survivors	who	inherit	a	germline	gene	
mutation	from	their	parent	at	higher	risk	of	another	cancer	than	survivors	with	a	de	novo	
germline	mutation?	The	aim	of	this	analysis	was	to	estimate	the	risk	of	second	cancers	in	
long-term	survivors	of	RB	according	to	the	classification	of	germline	mutation,	using	
surrogate	measures	based	on	family	history	and	laterality	of	the	RB.	
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7.2	Methods	
	We	assembled	a	cohort	of	1852	eligible	one-year	survivors	of	RB	from	two	
hospital	centres	in	the	US.		Based	on	data	abstracted	from	medical	records,	we	classified	
survivors	as	either	bilateral	(n=1036,	55.9%)	or	unilateral	(n=816,	44.1%).		We	defined	a	
positive	family	history	as	either	a	first-	or	second-degree	relative	with	RB.		We	excluded	
having	a	child	with	RB	as	evidence	of	family	history,	because	not	all	subjects	would	have	
had	children	nor	would	it	have	been	mentioned	in	the	original	medical	record.		We	then	
cross-classified	survivors	into	four	groups	for	analysis	(Table	7.1).	
Table	7.1	Classification	by	laterality	and	family	history	of	retinoblastoma	
Group	 Bilateral	 Positive	family	
history	of	RB	
Number	and	%	
1	 Yes	 Yes	 199	(10.7)	
2	 Yes	 No	or	unknown	 837	(45.2)	
3	 No	 Yes	 36	(2.0)	
4	 No	 No	or	unknown	 780	(42.1)	
	
We	confirmed	second	cancers	by	pathology	reports	(62.8%),	hospital	records	
(15.2%),	autopsy	reports	(3.4%)	or	death	certificates	(18.6%).		We	included	
pineoblastoma,	an	intracranial	tumour	often	referred	to	as	trilateral	RB,	as	a	second	
cancer.	It	occurs	in	less	than	10%	of	bilateral	RB	patients	and	is	usually	diagnosed	at	least	
20	months	after	the	bilateral	RB	(Rodriguez-Galindo	et	al.,	2015).		We	excluded	all	in-situ	
cancers	(except	bladder),	benign	tumours	and	non-melanoma	skin	cancers,	because	
general	population	incidence	rates	for	these	tumours	are	not	available	in	the	US.	
Accrual	of	person	years	began	one	year	after	entry	into	the	cohort	and	ended	on	
the	date	of	second	cancer	diagnosis,	date	of	death,	date	last	known	alive	or	end	of	study	
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(December	31,	2001	for	survivors	diagnosed	prior	to	1985	(Cohort	1)	and	December	31,	
1998	for	survivors	diagnosed	with	RB	≥	1985	(Cohort	2),	whichever	occurred	earliest.	
Three	types	of	analysis	were	conducted	that	focused	on	the	risk	of	all	second	
cancers	and	specifically	bone	cancer,	soft	tissue	sarcomas	and	melanomas.		These	
cancers	were	selected	because	they	were	the	most	common	type	of	second	cancers.	We	
calculated	SIRs	compared	with	general	population	expected	rates	for	all	four	groups	of	
survivors.	Univariate	and	multivariate	Poisson	regression	models	were	conducted	taking	
into	account	other	risk	factors	but	were	restricted	to	bilateral	survivors	only,	because	the	
focus	of	the	paper	was	on	the	difference	between	modes	of	transmission	of	germline	
mutations.			The	cumulative	incidence	of	second	cancers	up	to	50	years	after	RB	
diagnosis	was	determined	for	all	four	groups.	
7.3	Main	Findings	
Overall,	13%	of	all	RB	survivors	had	a	positive	family	history	of	RB	(11%	bilateral	
and	2%	unilateral).		Table	7.2	presents	selected	characteristics	of	the	4	groups.			The	
median	follow-up	was	less	for	the	bilateral	survivors	with	a	family	history	compared	with	
those	without	(19	yrs	versus	26	yrs),	whereas	the	unilateral	survivors	had	similar	years	of	
follow	up	for	those	with	and	without	a	family	history	(25	yrs	versus	28	years).			Not	
unexpectedly,	both	bilateral	and	unilateral	patients	with	a	family	history	were	
significantly	more	likely	to	be	diagnosed	with	RB	at	a	younger	age.		
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Table	7.2.	Characteristics	of	1852	1-year	survivors	of	retinoblastoma,		
	 Bilateral	(n=1036)	 Unilateral	(n=816)	
	 	 Family	history	 No	family	history
a
	 Family	history	 No	family	history
b
	
Characteristic	 No.	 %	 No.	 %	 No.	 %	 No.	 %	
No.		Survivors	 199	 10.7	 837	 45.2	 36	 1.9	 780	 42.1	
Sex	 	 	 	 	 	 	 	 	 	
Male	 	 107	 53.8	 434	 51.8	 20	 55.6	 395	 50.6	
Female	 	 92	 46.2	 403	 48.2	 16	 44.4	 385	 49.4	
	 	 	 	 	 P=0.626	 	 	 	 P=0.564	
Age	at	Rb	 	 	 	 	 	 	 	 	 	
<12	months	 	 153	 76.9	 454	 54.2	 19	 52.8	 173	 22.2	
12-23	months	 	 29	 14.6	 251	 30.0	 10	 27.8	 224	 28.7	
24+	months	 	 17	 8.5	 132	 15.8	 7	 19.4	 383	 49.1	
	 	 	 	 	 P<0.001	 	 	 	 P<0.001	
Calendar	yr	RB	 	 	 	 	 	 	 	 	
<1960	 	 45	 22.6	 252	 30.1	 5	 13.9	 178	 22.8	
1960-69	 	 48	 24.1	 245	 29.3	 8	 22.2	 205	 26.3	
1970-79	 	 45	 22.6	 195	 23.3	 12	 33.3	 196	 25.1	
1980+	 	 61	 30.7		 145	 17.3	 11	 30.6	 201	 25.8	
Median	year	 	 1970	 1966	 1975	 1970	
	 	 	 	 	 P<0.001	 	 	 	 P=0.448	
Radiation	 	 	 	 	 	 	 	 	 	
Yes	 	 184	 92.5	 747	 89.3	 20	 55.6	 138	 17.7	
No	 	 14	 7.0	 87	 10.4	 16	 44.4	 635	 81.4	
Unknown	 	 1	 0.5	 3	 0.3	 0	 0	 7	 0.9	
	 	 	 	 	 P=0.344	 	 	 	 P<0.001	
Chemotherapy	 	 	 	 	 	 	 	 	
Yes	 	 72	 36.2	 349	 41.7	 5	 13.9	 101	 12.9	
No	 	 123	 61.8	 474	 56.6	 31	 86.1	 669	 85.8	
Unknown	 	 4	 2.0	 14	 1.7	 0	 0	 10	 1.3	
	 	 	 	 	 P=0.334	 	 	 	 P=0.784	
Attained	age	 	 	 	 	 	 	 	 	
<10	years	 	 47	 23.6	 183	 21.9	 3	 8.3	 113	 14.5	
10-19	years	 	 55	 27.6	 139	 16.6	 5	 13.9	 101	 12.9	
20-29	years	 	 29	 14.6	 136	 16.2	 13	 36.1	 169	 21.7	
30-39	years	 	 46	 23.1	 224	 26.8	 11	 30.6	 186	 28.9	
40+	years	 	 22	 11.1	 155	 18.5	 4	 11.1	 211	 27.0	
	 	 	 	 	 P=0.002	 	 	 	 P=0.077	
Median	follow	up	yrs	
and	range	 19	(1-55)	 26	(1-69)	 25	(1-56)	 28	(1-77)	
a	
includes	653	no	and	184	unknown	family	history	for	bilateral	survivors		
B
	includes	641	no	and	139	unknown	family	history	for	unilateral	survivors
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We	observed	significantly	elevated	SIRs	for	all	second	cancers	combined	in	
bilateral	survivors	with	a	family	history	(SIR=36)	compared	with	those	without	a	family	
history	(SIR=19)	(P=<0.001).	We	noted	a	similar	pattern	in	unilateral	survivors	with	a	
family	history,	based	on	much	smaller	number	of	second	cancers	(SIR=7.1	versus	SIR=1.5,	
P=0.004).		SIRs	for	melanoma	were	also	significantly	higher	for	bilateral	survivors	with	a	
family	history	compared	with	those	with	no	family	history	(P=0.004).		Risks	were	
increased	for	cancers	of	the	bone,	soft	tissue,	eye/orbit	and	nasal	cavities	independent	of	
family	history.		(See	table	7.3).		
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Table	7.3	Risk	of	second	cancer	in	1,852	1-year	survivors	of	retinoblastoma	
	 	 	
Retinoblastoma	 	 Bilateral	 Unilateral	 	
		 		 		 Family	history	 No	family	history*	 Family	history	 No	family	history*	 		
No.	survivors	 	 199	 837	 36	 780	 	
Person-years	 	 4,065	 19,739	 898	 20,504	 	
Cancer	Site	(ICD-O	classification)	 	
All	cancers		
(140-172,174-207)	
O†	 56
a
	 188
b
	 3
c
	 22d	 	
Exp	 1.6	 10.1	 0.4	 14.5	 	
SIR	 35.8	 19	 7.1	 1.52	 	
95%CI	 (27-46)	 (16-22)	 (1.5-21)	 (0.9-2.3)	 	
AER	 133	 90	 29	 3.7	 	
Bone	(170)	 O	 15	 62	 0	 0	 	
	
Exp	 0.03	 0.16	 0.01	 0.17	 	
SIR	 459	 388	 0	 0	 	
95%CI	 (259-757)	 (297-497)	 (0-460)	 (0-21)	 	
AER	 37	 35	 -0.09	 -0.08	 	
Soft	tissue		(171,	192.4-.5)	
O	 10	 25	 1	 0	 	
Exp	 0.04	 0.21	 0.01	 0.23	 	
SIR	 233	 118	 106	 0	 	
95%CI	 (112-428)	 (76-174)	 (2.7-594)	 (0.0-16)	 	
AER	 24	 13	 11	 -0.11	 	
Cutaneous	Melanoma	
(173,	M8720-8790)	
O	 8	 15	 1	 0	 	
Exp	 0.12	 0.77	 0.03	 0.99	 	
SIR	 65.5	 19.6	 35	 0	 	
95%CI	 (29-129)	 (11-32)	 (0.9	-193)	 (0-3.6)	 	
AER	 19	 7.2	 6.3	 -0.5	 	
Eye/orbit		
(190)	
O	 2	 8	 0	 0	 	
Exp	 0.01	 0.05	 0	 0.05	 	
SIR	 177	 155	 0	 0	 	
95%CI	 (21-640)	 (67-305)	 (0->1000)	 (0-73)	 	
AER	 4.9	 4.0	 -0.02	 -0.02	 	
Nasal	cavities	(160)	 O	 7	 22	 0	 0	 	
Exp	 0.01	 0.02	 0	 0.03	 	
SIR	 2000	 1041	 0	 0	 	
95%CI	 (803->1000)	 (652->1000)	 (0->1000)	 (0-132)	 	
AER	 17	 11	 -0.01	 -0.01	 	
Brain,	CNS		
(191-192)	
	
O	 2	 9	 0	 2	 	
Exp	 0.12	 0.57	 0.03	 0.63		 	
SIR	 16.7	 15.7	 0.0	 3.2		 	
95%CI	 (2.0-60)	 (7.2-30)	 (0-146)	 (0.4-11)	 	
AER	 4.6	 4.3	 -0.28	 0.7	
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Pineoblastoma	 O	 6	 2	 0	 0	 	
(194.4)	 Exp	 0.01	 0.04	 0.0	 0.04	 	
	 SIR	 584	 44.5	 0.0	 0.0	 	
	 95%CI	 (214->1000)	 (5.4-161)	 (0->1000)	 (0-82)	 	
	 AER	 14.7	 1.0	 -0.02	 -0.02	 	
*	No	family	history	includes	unknown	family	history	
†O=observed	no.	of	cancers;	Exp=expected	no.	of	cancers,	SIR=Standardised	incidence	ratio;		
CI=confidence	interval;	AER=Absolute	excess	risk	(Obs-Exp/person	years	x	10,000)	
a
	Other	cancers	include	2digestive	(1colon,1	small	intestine),		
1	other	respiratory,	1	acute	lymphocytic	leukaemia,	and	2	unknown	site	
b	other	cancers	include	2	tongue,	2	salivary	gland,	2	nasopharynx,	2	colon,	3	lung,	3	other	respiratory,	8	female	breast,				
1	male	breast,	5	corpus	uteri,	1	testis,	1	kidney,	3	bladder,	2	thyroid,	1	NHL,	2	Hodgkin	lymphoma,	1	lymphocytic	leukaemia		
NOS,	and	6	unknown	primary	site	
c
	other	cancer	includes	one	Hodgkin	lymphoma		
d
	other	cancers	include	7	female	breast	cancers,	2	thyroid,	2	uterine	corpus	,	1	rectum,	1	prostate,	1	kidney,		
1	Hodgkin	lymphoma,	1	acute	myeloid	leukaemia,	and	4	unknown	primary	sites.	
	
We	noted	a	modestly	elevated	relative	risk	(RR)	for	all	second	cancers	combined	
associated	with	family	history	in	bilateral	survivors	(RR=1.37,	95%CI	1.00-1.86,	P=0.05)	
adjusted	for	treatment,	age	and	length	of	follow-up.	A	stronger	association	was	noted	for	
melanoma	(RR=3.08,	95%CI	1.23-7.16,	P=0.02),	but	not	for	bone	cancer	or	soft	tissue	
sarcoma.		Aside	from	family	history,	the	other	risk	factors	associated	with	increased	risk	
of	second	cancers	included	radiotherapy	(P=0.001)	and	older	attained	age	(P<0.001).		
Both	risk	factors	were	also	significantly	increased	for	bone	cancer	and	soft	tissue	
sarcomas,	whereas	risks	for	melanoma	were	associated	with	older	attained	age	(>25	
years)	and	earlier	calendar	year	of	diagnosis	(<1970)	but	not	radiotherapy.		
Cumulative	incidence	of	all	second	cancers	at	50	years	after	RB	diagnosis	was	
higher	for	bilateral	survivors	with	a	family	history	of	RB	compared	with	those	without	a	
family	history	(47%,	95%CI	35%-59%	compared	with	38%,	95%CI	32%-44%,	P=0.004)	
(Figure	7.1).		A	similar	pattern	was	observed	among	the	unilateral	survivors	with	and	
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without	a	family	history	of	RB,	based	on	small	numbers	of	second	cancers	(18%,	95%	CI	
0.0%-42%	and	8%,	95%	CI	3%-13%).		Consistent	with	the	multivariate	analyses,	the	
cumulative	incidence	did	not	differ	by	family	history	for	bone	or	soft	tissue	sarcoma,	but	
did	differ	for	melanoma	(9%,	95%CI	3%-15%	compared	with	2%,	95%	CI	0.9%-4.0%).
	
Figure	7.1.	Cumulative	incidence	percent	of	second	cancers	by	decade	up	to	50	
years	after	retinoblastoma	diagnosis	in	1,852	1-year	survivors	of	retinoblastoma	by	
family	history	and	laterality	
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7.4	Significance	
This	was	the	first	report	to	estimate	the	risk	of	second	cancers	in	long-term	
survivors	of	RB	by	the	presence	of	an	inherited	or	de	novo	germline	mutation	taking	
treatment	and	other	risk	factors	into	account	(Kleinerman	et	al.,	2012).	Using	laterality	of	
and	family	history	of	RB	as	surrogate	measures	of	mutation	status,	we	showed	that	a	
presumed	inherited	germline	mutation	confers	a	37%	increased	risk	for	a	second	cancer,	
adjusted	for	treatment,	age	and	length	of	follow-up	compared	with	survivors	with	a	de	
novo	germline	mutation.		An	even	stronger	association	with	family	history	was	noted	for	
melanoma,	but	not	for	bone	cancer	or	soft	tissue	sarcoma.		Consistent	with	these	
findings,	the	cumulative	incidence	of	a	second	cancer	50	years	after	RB	diagnosis	was	
highest	for	bilateral	survivors	with	a	family	history,	followed	by	bilateral	survivors	
without	a	family	history,	unilateral	survivors	with	a	family	history	and	unilateral	survivors	
with	no	family	history.		
Among	the	three	most	common	tumours	after	RB	that	we	investigated,	
melanoma	was	the	only	one	to	be	consistently	related	to	family	history	of	RB.		Not	
unexpectedly,	melanoma	was	also	increased	in	survivors	older	than	age	25	and	those	
treated	prior	to	1970.		Melanoma	typically	starts	to	increase	in	incidence	in	the	20s	
(Bradford	et	al.,	2010)	consistent	with	the	trend	that	we	observed.		In	contrast	to	bone	
cancer	and	soft	tissue	sarcoma,	increased	risk	for	melanoma	was	not	associated	with	
radiotherapy.		These	findings	indicate	that	having	an	inherited	germline	RB1	mutation	
may	predispose	to	melanoma	and	that	there	is	a	strong	genetic	component.	
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Treatment	exerted	a	stronger	influence	for	the	development	of	bone	cancer	and	
soft	tissue	sarcoma.		This	was	of	interest	but	not	too	surprising	since	a	radiation	dose	
response	has	been	demonstrated	for	both	of	these	tumours	(Hawkins	et	al.,	1996,	Tucker	
et	al.,	1987,	Wong	et	al.,	1997).	
	
Table	7.4	Relative	risks	for	the	three	most	common	cancers	in	bilateral	retinoblastoma	
survivors.	
Risk	Factor	 Bone	 STS	 Melanoma	
	 RR	95%CI	 RR	95%CI	 RR	95%CI	
Family	History	RB	(yes/no)	 0.92(0.5-1.6)*	 0.99	(0.5-1.9)	 3.08		(1.2-7.2)	
Age	at	RB	(≥24	months)	 0.71	(0.3-1.4)	 0.19	(0.03-0.6)	 0.45(0.1-1.6)	
Calendar	Yr	RB	(<1970)	 0.93	(0.6-1.6)	 0.87	(0.4-1.8)	 5.99	(1.2-110)	
Sex	(Female)	 0.92	(0.6-1.5)	 0.76	(0.5-1.3)	 1.92	(0.8-4.7)	
Radiotherapy	(yes/no)	 7.05	(1.6-125)	 7.16	(1.6-127)	 1.46	(0.4-9.3)	
Chemotherapy	(yes/no)	 1.71	(1.1-2.8)	 1.32	(0.8-2.2)	 0.83	(0.4-2.0)	
Attained	Age	(≥40	years)	 0.33	(0.02-1.6)	 5.01	(1.6-14)	 6.28	(2.6-18)¶		
*Relative	risks	adjusted	for	all	of	the	other	risk	factors	other	than	one	of	interest.	
¶	Attained	age	≥25	years	
	 	
This	analysis	was	conducted	differently	than	previous	analyses	in	order	to	address	
the	question	of	family	history	and	risk.		We	did	not	assign	survivors	to	hereditary	and	
non-hereditary	categories.	Although	it	was	clear	that	there	was	an	increased	risk	of	
second	cancers	among	unilateral	survivors	with	a	family	history	reported,	we	decided	not	
to	combine	these	36	survivors	with	the	bilateral	survivors.		These	unilateral	survivors	
were	phenotypically	different	from	the	bilateral	patients	and	their	germline	mutations	
may	represent	mosaicism	with	incomplete	penetrance	of	the	RB1	mutation.		
A	weakness	of	the	analysis	was	the	reliance	on	surrogate	measures	of	the	
mutation	status	rather	than	mutation	testing	data.	Although	laterality	is	a	reliable	
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measure,	family	history	is	subject	to	misclassification	if	it	is	not	recorded	in	the	medical	
record.		It	is	likely	that	family	history	could	have	been	under-reported	in	the	medical	
records,	which	would	bias	the	results	towards	the	null.	We	had	restricted	knowledge	of	
family	history	to	the	original	medical	record	rather	than	rely	on	subsequent	reporting	by	
a	survivor	on	a	questionnaire.	Using	additional	data	from	questionnaires	could	bias	the	
results	in	the	other	direction	if	those	with	a	family	history	were	more	likely	to	answer	the	
questionnaire.	The	proportion	of	survivors	in	our	study	with	a	positive	family	history	was	
consistent	with	other	population-based	studies	(Houdayer	et	al.,	2004,	Marees	et	al.,	
2010).	
Moll	et	al.	(Moll	et	al.,	2012)	in	a	letter	to	the	editor	raised	the	possibility	that	
mosaicism	in	those	hereditary	survivors	with	a	de	novo	RB1	germline	mutation	could	
account	for	a	lower	risk	of	second	cancers	compared	with	survivors	with	an	inherited	
germline	mutation.	Due	to	mosaicism,	not	all	cells	carry	the	RB1	mutation	and	this	could	
explain	the	lower	risk	of	second	tumours	(Kaye	and	Harbour,	2004).	Moll	et	al	(Moll	et	al.,	
2012)	point	out	that	between	6-10%	of	de	novo	mutations	may	be	mosaic.			
In	response	to	their	concern	(Kleinerman	et	al,	2012,	Reply	to	AC	Moll),	we	
estimated	what	the	relative	risk	of	a	second	cancer	would	be	if	the	rate	of	mosaicism	was	
10%	in	our	cohort	as	suggested	by	Moll.		At	a	rate	of	10%,	we	were	able	to	detect	
significant	differences	in	overall	risk	of	second	cancers.		We	then	estimated	that	the	rate	
of	mosaicism	would	have	to	be	as	high	as	30%	in	the	de	novo	survivors	in	order	to	no	
longer	detect	a	significance	difference	in	risk	of	second	cancers.	We	agreed	that	the	
difference	in	risk	could	be	attributed	partially	to	mosaicism,	although	we	have	no	
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information	on	the	prevalence	of	mosaicism	in	our	study,	however,	the	difference	could	
also	be	attributed	to	the	penetrance	of	the	RB1	mutations	or	perhaps	modifier	genes	in	
the	families.	
Interestingly,	two	recent	studies	on	the	frequency	of	mosaicism	in	RB1	sporadic	
patients	indicate	that	low-level	mosaic	variants	ranged	from	8-24%	in	40	RB	patients	
(Amitrano	et	al.,	2015)	and	10%	in	140	RB	patients	(Dommering	et	al.,	2014).	
Unfortunately	we	do	not	have	mutation	testing	available	for	our	entire	cohort	in	order	to	
estimate	the	level	of	mosaicism.		
7.5	Public	Health	Message	
Hereditary	RB	survivors	with	an	inherited	germline	mutation	should	undergo	
annual	skin	examinations	starting	in	adolescence	to	identify	early	signs	of	melanoma.		
7.6	Role	in	study	
Role:		I	initiated	the	idea	for	the	analysis,	reviewed	the	literature	and	drafted	the	
manuscript.	Study	team:	Dr	Little	was	the	consulting	statistician,	Dr	Yu,	a	post-doctoral	
fellow	whom	I	mentored,	conducted	the	analysis	with	consultation	from	Dr	Li.	Drs	
Abramson	and	Seddon	were	the	clinical	collaborators	and	provided	the	patients;	Dr	
Tucker	was	the	senior	study	investigator.	My	contribution:	80%		
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Chapter	8. Chemotherapy	and	Radiotherapy	
Wong	JR,	Morton	LM,	Tucker	MA,	Abramson	DH,	Seddon	JM,	Sampson	JN,	
Kleinerman	RA.	Risk	of	subsequent	malignant	neoplasms	in	long-term	retinoblastoma	
survivors	following	chemotherapy	and	radiotherapy.	J	Clin	Oncol,	32:3284-3290,	2014.	
8.1	Introduction	and	rationale	
Hereditary	retinoblastoma	survivors	are	at	risk	of	developing	second	cancers	due	
to	radiotherapy,	but	patients	are	increasingly	being	treated	with	chemotherapy	and	little	
is	known	about	risks	of	second	cancers	related	to	chemotherapy.		Previous	analyses	in	
this	cohort	suggested	increased	risks	for	those	treated	with	chemotherapy	compared	
with	those	not	treated	with	chemotherapy.	However,	no	detailed	analyses	exploring	
chemotherapy	on	the	risk	of	second	cancers	have	previously	been	conducted.		
8.2	Methods	
For	this	analysis,	we	focused	on	the	risk	of	second	cancers	in	5-year	survivors	of	
hereditary	RB	(n=906)	in	cohorts	1	and	2,	because	treatment	effects	were	not	likely	to	
occur	earlier.			The	majority	of	these	survivors	were	treated	with	radiotherapy	(n=813,	
89.7%)	and	43%	(n=336)	of	those	also	received	chemotherapy.		Only	80	survivors	
(n=10%)	received	surgery	alone	and	very	few	received	only	chemotherapy	(n=13,	<0.1%).			
We	estimated	risks	of	all	second	cancers	combined,	for	the	three	most	common	
second	cancers	(bone	cancer,	soft	tissue	sarcoma	and	melanoma)	and	for	epithelial	
tumours	combined	(breast,	lung,	thyroid,	bladder,	colorectal,	kidney,	nasal	cavity,	
prostate,	tongue	and	uterus)	compared	with	the	general	population	rates	for	these	
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cancers.		SEER	data	were	used	to	generate	expected	rates	of	these	cancers	from	the	US	
general	population	in	order	to	calculate	SIRs.		Person-years	began	being	counted	5	years	
after	RB	diagnosis	and	ended	on	the	date	of	second	cancer	diagnosis,	death,	lost	to	
follow	up	or	last	contact,	whichever	occurred	earliest.		Follow-up	for	this	analysis	was	up	
through	2009	based	on	the	date	of	the	last	contact	with	study	subjects.	
We	used	a	Cox	proportional	hazard	regression	model	with	age	as	the	time	scale	to	
evaluate	the	risk	of	second	cancers	among	those	treated	with	chemotherapy	and	
radiotherapy	and	for	different	chemotherapy	subgroups	relative	to	those	treated	with	
radiotherapy	alone.		Because	we	had	not	collected	treatment	for	any	of	the	second	
cancers,	we	included	a	time-dependent	indicator	variable	for	those	survivors	who	
developed	a	second	cancer	other	than	the	second	cancer	of	interest.			We	also	stratified	
models	by	calendar	year	of	diagnosis	to	account	for	changes	in	treatment	practices	over	
time.		Most	patients	were	treated	with	TEM	prior	to	1970,	whereas,	many	other	
alkylating	agents	were	used	after	that	time.		
Other	exploratory	analyses	included	risks	by	SIRs	by	attained	age	(<25,	≥25	years	
at	RB	diagnosis),	location	of	the	second	cancer	in	relation	to	the	radiotherapy	field	(in	or	
outside),	and	an	estimate	of	the	cyclophosphamide	equivalent	dose	for	specific	
chemotherapies.	
Cumulative	incidence	for	all	of	the	second	cancer	groups	and	specific	subtypes	
were	calculated	taking	into	account	the	competing	risk	of	death	and	loss	to	follow	up.		
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8.3	Main	findings	
Among	the	813	survivors	treated	with	either	radiotherapy	with	or	without	
chemotherapy,	33%	(n=265)	developed	at	least	one	second	cancer	and	6%	(n=46)	
developed	more	than	one.		The	median	follow-up	was	26.3	years	(0.6-63	years).	
SIRs	for	the	risk	of	second	cancers	significantly	differed	for	those	treated	with	
radiotherapy	compared	with	radiotherapy	plus	chemotherapy	(Obs=135,	SIR=20.4,	95%	
CI	17.1-24.2	and	Obs=130,	SIR=26.4,	95%CI	22.0-31.3;	P=0.04)	(See	Table	8.1).			SIRs	were	
significantly	greater	for	those	treated	with	chemotherapy	and	radiotherapy	compared	
with	radiotherapy	for	bone	cancers	(P=0.03)	and	LMS	(P<0.001).		We	did	not	observe	
similar	differences	for	SIRs	for	by	treatment	other	soft	tissue	sarcomas,	melanomas	or	
epithelial	tumours.		
The	results	of	the	hazards	ratio	models	indicated	similar	findings	as	the	SIR	
analyses.	Chemotherapy	and	radiotherapy	were	related	to	a	significantly	increased	risk	
for	all	second	cancers	combined	(HR=1.31,	95%	CI	1.02-1.68)	compared	with	
radiotherapy	alone.		Risks	for	bone	cancer	(HR=1.73,	95%	CI	1.13-2.67)	and	
leiomyosarcoma	(HR=2.61,	95%	CI	1.19-5.70)	were	significantly	increased.		Estimating	
risks	separately	for	alkylating	agents	and	radiotherapy	and	for	TEM	and	radiotherapy	
indicated	increased	risks	for	bone	tumours	associated	with	alkylating	agents	(HR=1.60,	
95%	CI	1.03-2.49)	and	for	LMS	with	both	alkylating	agents	(HR=2.67,	95%CI	1.22-5.85)	
and	TEM	(HR=3.21,	95%CI	1.40-7.39).		
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Cumulative	incidence	of	second	cancers	at	50	years	after	RB	diagnosis	for	
survivors	treated	with	radiotherapy	compared	with	radiotherapy	and	alkylating	agents	
indicated	significant	differences	only	for	leiomyosarcoma	(P=0.02).		
Table	8.2.	Cumulative	incidence	of	subsequent	cancers	after	hereditary	retinoblastoma	
by	treatment	received	
	
Radiotherapy	
Cumulative	incidence	(%)	and	95%	
confidence	intervals	at	attained	age	of:	
Alkylating	Agent	with	
Radiotherapy	
Cumulative	incidence	(%)	and	95%	
confidence	intervals	at	attained	age	of:	
	
Type	of	second	
cancer	 25	years	 50	years	 25	years	 50	years	 P	
Bone		 8.4	(5.2-11.6)	 13.0	(2.1-23.9)	 11.7	(7.4-16.0)	 14.7	(3.9-25.5)	 0.16	
Leiomyosarcoma	 0.5	(0.0-1.3)	 6.3	(0.0-14.3)	 0.7	(0.0-1.8)	 8.7	(0.0-17.4)	 0.02	
Other/unspecified	
soft	tissue	sarcoma	
4.8	(2.3-7.3)	 15.5	(3.5-27.5)	 3.3	(0.9-5.7)	 9.2	(0.4-18.0)	 0.35	
Melanoma	 1.0	(0.0-2.2)	 7.1	(0.0-15.5)	 1.0	(0.0-2.3)	 4.9	(0.0-11.7)	 0.34	
	
Exploratory	analyses	by	age	at	RB	diagnosis	indicated	that	there	was	no	
difference	in	risk	for	all	second	cancers	combined	for	those	who	received	alkylating	
agents	before	and	after	one	year	of	age.		However,	the	association	of	risk	with	age	was	
stronger	for	leiomyosarcoma	in	survivors	who	were	treated	with	alkylating	agents	at	less	
than	one	year	compared	with	over	one	year	(HR=5.2	vs.	HR=1.8,	P=0.08).			
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Risks	for	individual	second	cancers	(leiomyosarcoma	and	melanoma)	were	not	
related	to	location	of	the	tumour	in	relation	to	the	radiotherapy	field.	However,	risk	for	
bone	cancers	did	differ	by	location	in	relation	to	the	radiation	field	(HR=	2.28,	95%CI	
1.02-5.11	for	infield	and	HR=1.44,	95%CI	0.82-2.52	for	outside	the	field).		
8.4	Significance	
We	had	previously	evaluated	risks	for	soft	tissue	sarcomas	in	relation	to	
chemotherapy	but	not	as	detailed	as	the	current	analyses.		This	report	provided	
quantitative	evidence	that	the	risks	for	both	bone	tumours	and	leiomyosarcoma	are	
higher	for	hereditary	survivors	who	had	been	treated	with	alkylating	agents	and	radiation	
compared	with	those	who	were	treated	with	radiation	alone.	Our	data	are	consistent	
with	a	previous	UK	case-control	study	of	bone	cancers	in	RB	survivors	that	reported	a	
non-significant	2.1-fold	risk	of	bone	cancers	in	those	who	received	chemotherapy	and	
radiation	compared	with	radiation	alone	(Hawkins	et	al.,	1996).		The	findings	for	
leiomyosarcoma	are	also	in	agreement	with	another	UK	study	of	childhood	cancer	
survivors	that	found	a	positive	dose-response	for	chemotherapy	(alkylating	agents)	for	
soft	tissue	sarcomas	(Jenkinson	et	al.,	2007).	Unfortunately,	we	had	too	few	survivors	
treated	with	chemotherapy	alone	to	evaluate	the	risk	of	second	cancers	in	that	group	
and	we	lacked	dose	data	to	demonstrate	a	dose-response.		These	data	provide	further	
evidence	of	risks	of	bone	cancer	and	leiomyosarcomas	in	RB	survivors	who	were	
previously	treated	with	both	alkylating	agents	and	radiation.	Although	these	survivors	
were	treated	mainly	with	TEM,	which	is	no	longer	used,	current	chemotherapies	include	
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other	alkylating	agents	that	have	similar	toxicity	(Rodriguez-Galindo	et	al.,	2015).	This	
makes	these	data	relevant	to	the	current	use	of	chemotherapy	used	to	treat	RB	patients.		
8.5	Public	Health	Message	
The	higher	risks	for	bone	tumours	and	leiomyosarcomas	associated	with	
alkylating	agents	and	radiation	treatment	should	increase	awareness	of	the	potential	
chemotherapy-related	risks	for	second	cancers	in	long-term	survivors.		
8.6	Role	in	study		
Role:	I	initiated	the	idea	for	the	study	and	contributed	to	the	interpretation	of	the	
data	and	preparation	of	the	manuscript.	Study	team:	Ms	Wong	was	a	pre-doctoral	
student	whom	I	mentored	and	she	conducted	the	analyses	and	wrote	the	manuscript.	
Drs	Morton	and	Tucker	were	senior	study	investigators,	Dr	Sampson	was	the	statistician	
and	the	clinical	collaborators	were	Drs	Abramson	and	Seddon.	My	contribution:	55%.		
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Chapter	9. Summary	
9.1	Summary	
In	this	series	of	studies	conducted	by	the	author	in	a	hospital-based	retrospective	
cohort	of	1852	long-term	survivors	of	retinoblastoma,	survivors	with	a	RB1	germline	
mutation	have	an	increased	risk	for	second	cancers	mainly	due	to	the	occurrence	of	
three	types	of	cancers:	soft	tissue	sarcomas,	bone	cancers	and	melanoma.	Second	cancer	
risks	persist	for	decades,	and	by	age	50,	one	in	three	hereditary	survivors	and	one	in	20	
non-hereditary	survivors	will	develop	a	second	cancer.		
The	two	major	contributing	causes	to	second	cancers	in	this	cohort	were	having	a	
germline	RB1	mutation	and	treatment	of	RB	with	radiation.		Over	85%	of	hereditary	
patients	received	radiation	treatment	and	this	clearly	increased	the	risk	of	many	second	
cancers,	primarily	bone	and	soft	tissue	sarcomas	that	were	previously	shown	to	be	dose-
related	(Wong	et	al.,	1997).	Although	chemotherapy	in	combination	with	radiotherapy	
increased	the	risk	of	some	second	cancers,	notably	bone	sarcomas,	the	role	of	
chemotherapy	was	not	as	clear	due	to	small	number	of	survivors	treated	only	with	
chemotherapy.			
This	series	of	studies	presented	data	for	the	first	time	on	the	risk	of	soft	tissue	
sarcomas	by	histologic	subtype,	which	highlighted	the	greatest	risks	for	leiomyosarcomas	
in	this	population	(Kleinerman	et	al.,	2007).		In	particular,	an	increased	risk	of	uterine	
leiomyosarcoma	in	female	hereditary	survivors	was	identified	that	was	followed	up	by	a	
more	in-depth	evaluation	of	the	risk	(Francis	et	al.,	2012).		
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Risks	for	individual	epithelial	tumours	of	adulthood	following	treatment	for	
hereditary	RB	were	not	as	clear	in	these	data	likely	due	to	small	numbers.	Lung	and	
breast	cancers	were	the	most	frequently	reported	epithelial	cancers	in	these	survivors.		
Somatic	mutations	in	the	RB1	gene	have	been	reported	in	non-small	cell	lung	cancer	
(Harbour	et	al.,	1988)	and	in	breast	cancer	(Bosco	and	Knudsen,	2007).		Lung	cancer	
mortality	was	significantly	elevated	in	hereditary	survivors,	but	risk	was	not	associated	
with	past	radiotherapy	for	RB	(Kleinerman	et	al.,	2000).		All	of	the	lung	cancer	cases	were	
smokers	suggesting	an	interaction	with	the	RB1	gene	or	perhaps	enhanced	susceptibility	
to	the	effects	of	tobacco.	Interestingly,	breast	cancer	risk	was	elevated	in	both	hereditary	
and	non-hereditary	survivors.	There	are	a	number	of	other	epithelial	cancers	that	have	
somatic	RB1	mutations	identified	in	their	pathways,	such	as,	bladder,	ovary	and	prostate,	
but	our	data	were	too	limited	to	be	able	to	show	significantly	increased	risks	of	cancer	of	
these	organ	sites.	
Genetic	predisposition,	i.e.,	RB1	germline	mutation,	also	contributes	to	these	
increased	risks	of	second	cancers.	We	provided	data	that	showed	for	the	first	time	that	
melanoma	risks	appear	to	be	higher	for	those	bilateral	survivors	who	inherit	a	RB1	
germline	mutation	from	a	parent	compared	with	those	bilateral	survivors	with	a	de	novo	
mutation	(Kleinerman	et	al.,	2012).		There	was	a	suggestion	in	our	data	that	the	risk	for	
all	second	cancers	combined	was	higher	for	those	with	an	inherited	RB1	germline	
mutation,	but	not	for	bone	or	soft	tissue	sarcoma	individually.	
My	colleagues	and	I	currently	have	genetic	studies	underway	with	this	cohort	to	
identify	genetic	variants	of	the	RB1	germline	mutations	that	may	be	related	to	the	risk	of	
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specific	second	cancers	in	hereditary	survivors.		Identification	of	specific	RB1	germline	
mutations	would	signal	those	survivors	at	highest	risk	of	a	second	cancer.		Future	work	
would	also	include	detecting	molecular	changes	that	characterize	second	cancers	in	
relation	to	radiotherapy	or	chemotherapy.	
9.2	Limitations	of	the	data	
The	source	of	the	population	was	hospital-based	rather	than	population-based	
and	included	only	two	institutions	that	may	potentially	limit	the	generalisability	of	the	
findings	to	the	general	population.	The	cohort	was	not	representative	of	the	true	
proportion	of	hereditary	patients	in	the	general	population,	because	it	included	a	much	
larger	proportion	of	hereditary	compared	with	non-hereditary	survivors	typically	found	in	
the	general	population.	However,	loss	to	follow-up	was	similar	in	both	groups	and	each	
group	was	independently	compared	with	the	general	population.	In	addition,	RB	is	a	rare	
cancer	and	second	cancers	are	rare,	so	the	inclusion	of	more	hereditary	survivors	
increases	the	value	of	the	population	to	identify	risks	of	second	cancers.	Treatment	
differed	greatly	by	hereditary	status	with	almost	all	hereditary	patients	receiving	
radiotherapy	(85%)	compared	with	a	very	small	proportion	of	non-hereditary	patients	
treated	with	radiotherapy	(15%).	This	could	have	confounded	the	results,	but	when	we	
stratified	the	risks	by	radiation	dose	in	three	categories	(high,	moderate	and	low),	we	
observed	the	highest	risks	for	organ	sites	in	the	head	region	that	received	the	highest	
doses	of	scatter	radiation.	
Because	we	did	not	conduct	mutation	testing	on	all	of	the	survivors	to	determine	
the	presence	of	a	germline	RB1	mutation,	we	did	not	know	whether	all	of	the	unilateral	
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patients	were	classified	correctly	as	non-hereditary.		Approximately	10%-15%	of	
unilateral	survivors	have	a	germline	mutation	that	is	less	penetrant	causing	only	one	eye	
to	be	affected.	We	relied	on	laterality	of	RB	and	mention	of	family	history	of	RB	in	the	
medical	record	to	determine	whether	a	survivor	was	likely	to	be	hereditary.		It	is	likely	
that	some	unilateral	RB	survivors	may	have	been	misclassified	as	non-hereditary,	due	to	
unknown	family	history	of	RB	or	a	less	penetrant	form	of	a	germline	RB1	mutation	
(mosaicism).		This	would	have	biased	the	risk	upward	for	second	cancers	in	the	non-
hereditary	survivors,	and	influenced	the	ratio	of	risks	of	hereditary:	non-hereditary	
towards	the	null.	But	given	the	very	large	increase	in	second	cancer	risk	in	the	hereditary	
patients,	the	misclassification	would	likely	have	had	a	very	small	effect.	Interestingly,	
when	we	restricted	the	unilateral	patients	with	a	family	history	whom	we	had	classified	
as	hereditary,	their	second	cancer	risk	resembled	that	of	the	bilateral	patients.		
For	the	incident	analyses,	we	had	to	rely	on	validated	self-reports	of	incident	
cancers	in	this	cohort,	because	there	is	not	national	cancer	registry	in	the	US.	We	were	
unable	to	contact	100%	of	the	cohort	in	the	most	recent	survey	that	we	conducted	and	
therefore	we	likely	missed	a	number	of	incident	cancers	or	conversely,	we	may	have	bias	
in	that	survivors	with	second	cancers	were	more	likely	to	respond	to	the	survey.		In	the	
future,	we	will	conduct	sensitivity	analyses	to	evaluate	the	extent	of	the	bias	in	the	
cohort.	We	can	also	make	the	assumption	that	all	non-responders	developed	the	second	
cancer	of	interest	and	calculate	a	SIR	and	compare	it	to	the	SIR	if	none	of	the	non-
responders	developed	the	cancer	of	interest	and	see	how	it	differs.	A	virtual	cancer	
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registry	in	the	US	is	in	development	and	in	a	few	years	when	it	is	up	available,	we	can	
match	our	cohort	to	ascertain	incident	cancers	more	efficiently	on	a	nation-wide	level.		
9.3	Disentangling	the	role	of	genetic	susceptibility	and	treatment	
All	of	these	studies	that	I	have	described	in	this	dissertation	have	been	focused	
primarily	on	hereditary	survivors	and	radiotherapy,	because	the	majority	of	the	
hereditary	survivors	were	treated	with	radiation	and	almost	all	of	the	second	cancers	
were	diagnosed	in	hereditary	survivors.	There	were	too	few	hereditary	survivors	who	
were	treated	by	surgery	alone	to	be	able	to	quantify	the	contribution	of	genetic	
susceptibility	in	the	absence	of	radiation.		We	formally	tested	an	interaction	between	
radiotherapy	and	genetic	susceptibility	for	increased	mortality	due	to	second	cancers,	
but	it	was	not	statistically	significant	(Yu	et	al.,	2009).			An	on-going	analysis	of	risk	
related	to	the	location	of	the	bone	and	soft	tissue	sarcoma	in	proximity	to	the	
radiotherapy	field	may	yield	some	data	on	this	issue	(Kleinerman	et	al,	in	preparation,	
2016).		In	the	current	analysis	I	am	finding	that	25%	of	the	bone	cancers	are	diagnosed	in	
the	lower	leg	are	diagnosed	only	up	to	age	25,	whereas	the	other	75%	of	bone	sarcomas	
are	diagnosed	in	the	head,	which	was	in	the	radiotherapy	field,	up	to	age	55	years.		The	
diagnosis	of	bone	sarcoma	in	the	lower	leg	is	clearly	not	related	to	radiotherapy	received	
by	the	eye.		Similarly,	the	increased	risk	of	uterine	leiomyosarcoma	indicates	a	likely	
genetic	predisposition,	because	the	scatter	dose	to	the	uterus	was	quite	small,	about	0.2	
Gray.		
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9.4	Changes	in	treatment	and	implications	for	cancer	screening	
Over	the	past	10	years,	treatments	for	RB	indicate	much	less	use	of	radiotherapy	
and	replacement	with	intra-arterial	or	intravitreal	chemotherapy	(Abramson	et	al.,	
2015b).			To	date,	there	are	no	formal	screening	guidelines	for	young	adult	or	adult	
survivors	of	RB.		Based	on	data	from	our	cohort	and	other	cohorts	in	the	UK	and	
Netherlands,	we	know	that	there	is	a	pool	of	survivors	treated	with	radiotherapy	in	the	
past	who	will	need	to	be	followed	for	future	bone	and	soft	tissue	sarcomas	of	the	head.		
Chemotherapy	(alkylating	agents)	was	related	to	the	incidence	of	bone	sarcomas	and	
leiomyosarcomas,	and	may	still	pose	a	risk	in	the	future	for	survivors.		Although	not	
related	to	radiotherapy,	hereditary	survivors	will	need	to	aware	of	increased	risks	
melanoma	and	lung	cancer.		The	risks	for	breast	cancer	related	to	treatment	are	not	
clear,	but	survivors	should	be	aware	of	possible	risks.		
9.5	Cancer	prevention	and	screening	recommendations	
I	had	evaluated	the	cancer	screening	behaviour	of	the	survivors	in	our	cohort	
based	on	responses	to	a	telephone	questionnaire	in	2000	(Sheen	et	al.,	2008).	We	found	
that	87%	of	females	had	a	Pap	test	within	the	past	2	years,	76%	of	females	age	>40	years	
reported	having	a	mammogram	within	the	past	2	years,	and	17.4%	of	males	had	
performed	monthly	testicular	self-examinations.	A	significantly	higher	proportion	of	
hereditary	compared	with	non-hereditary	survivors	reported	having	undergone	an	MRI	
or	CT	scan	in	the	past	5	years,	likely	due	to	second	cancers.	Higher	education,	greater	
contact	with	the	medical	care	system,	and	having	a	second	cancer	were	found	to	be	
associated	positively	with	most	screening	practices.	We	found	that	cancer	screening	
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behaviour	reported	by	RB	survivors	was	similar	to	national	screening	rates	for	breast,	
cervical,	and	testicular	cancer.		As	the	first	report	of	cancer	screening	practices	of	Rb	
survivors,	we	concluded	that	survivors	of	hereditary	RB	should	be	encouraged	to	
maintain,	if	not	increase,	their	current	screening	practices	to	ensure	early	detection	of	
second	cancers	in	this	high-risk	population.	
Unfortunately,	there	are	no	widely	used	screening	procedures	for	sarcomas	other	
than	possibly	using	whole	body	Magnetic	Resonance	Imaging	(WB-MRI)	that	does	not	
use	radiation	(Friedman	et	al,	2012)	or	F-18	Fluorodeoxyglucose-Positron	Emission	
Computed	Tomography	(PET)	screening,	which	does	includes	exposure	to	ionizing	
radiation	(Masciari	et	al.,	2008)	.		Both	Friedman	et	al	and	Masicari	et	al	performed	pilot	
studies	to	evaluate	the	utility	of	WB-MRI	and	PET	scans,	respectively,	to	detect	sarcomas	
in	childhood	cancer	survivors.		Neither	study	was	able	to	demonstrate	a	clear	advantage	
to	using	either	method	to	detect	sarcomas.	Based	on	these	studies	presented	in	this	
dissertation,	we	recommend	the	following	for	prevention	of	second	cancers:	
Table	9.1	Public	health	recommendations	to	prevent	second	cancers	based	on	
published	studies.	
9.6	Risk	factors		
The	following	chart	lists	the	relative	strength	of	risk	factors	related	to	the	main	
second	cancers	occurring	after	hereditary	RB	that	we	were	able	to	evaluate.		
Recommendation		 Rationale		 Source	
Avoid	smoking	or	if	a	smoker,	
make	an	effort	to	quit.			
Increased	mortality	from	lung	
cancer	in	hereditary	patients	
(Kleinerman	et	al.,	2000,	
Fletcher	et	al.,	2004)	
Reduce	sun	exposure	and	avoid	
tanning	beds.	Begin	regular	skin	
clinical	examinations	in	
adolescence.	
Increased	risk	of	melanoma	
starting	at	age	20	in	hereditary	
survivors	
(Kleinerman	et	al.,	2012).	
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Table	9.2	Risk	factors	for	selected	second	cancers	after	hereditary	retinoblastoma	
+++=strongly	associated,	++=moderately	associated,	+weakly	associated,	--	=not	
associated;	NE=not	evaluated	
9.7	What	we	still	need	to	learn	about	retinoblastoma	and	second	cancers	
	 The	role	of	chemotherapy	in	the	risk	of	second	cancers	in	retinoblastoma	
survivors	needs	to	be	clarified	further	and	is	becoming	an	important	issue	due	to	several	
factors:		
1)	Increasing	use	of	chemotherapy	is	replacing	radiotherapy	(Shinohara	et	al.,	
2014).	One	study	of	RB	survivors	that	evaluated	the	risk	of	second	cancers	after	systemic	
chemotherapy	only	followed	187	germline	patients	and	58	non-germline	patients	for	a	
mean	of	7	years	did	not	report	an	increased	risk	of	second	cancers,	however	that	study	
did	not	have	enough	person	time	to	have	adequate	power	to	evaluate	this	risk	(Turaka	et	
al.,	2012).	More	recently,	intra-arterial	and	intravitreal	delivery	of	chemotherapy	using	
interventional	radiation	therapy	to	direct	the	procedure	is	becoming	more	widely	used	
(Abramson	et	al.,	2015b).		It	is	not	known	what	the	long-term	effects	of	this	type	of	
Risk	Factor	 Bone	
Soft	
Tissue	
Sarcoma	 Melanoma	
Uterine	
Leiomyosarcoma	 Lung	
Family	History	RB	
(yes/no)	
--	 --	 +++	 NE	 NE	
Age	at	RB	 --	 ++	 --	 NE	 NE	
Calendar	Yr	RB	 --	 --	 ++	 NE	 NE	
Sex	 --	 --	 --	 +++	 ++	
Radiotherapy	
(yes/no)	
+++	 +++	 --	 +	 --	
Chemotherapy	
(yes/no)	
+++	 ++	 --	 +	 NE	
Older	Attained	
Age	(>25	yrs)	
++	 ++	 +++	 +++	 +++	
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delivery	will	be	in	terms	of	second	cancers	or	other	outcomes.		However,	it	is	thought	
that	the	avoidance	of	systemic	chemotherapy	would	reduce	the	risk	of	second	cancers	in	
these	survivors.		
2)	Increased	incidence	of	acute	myeloid	leukaemia	following	specific	systemic	
chemotherapies	such	as	alkylating	agents	and	epidophyllotoxins		(Morton	et	al.,	
2014b).		Leukaemia	has	been	reported	in	a	case	series	of	RB	survivors	treated	with	
chemotherapy	(Gombos	et	al.,	2007)	that	suggested	that	acute	myeloid	leukaemia	might	
be	increased	in	survivors	who	received	chemotherapy.	However,	acute	myeloid	
leukaemia	is	rare	and	a	large	number	of	survivors	would	need	to	be	assembled	in	order	
to	detect	a	risk.		
3)	Reports	of	risk	of	sarcomas	in	relation	to	specific	systemic	chemotherapies	
(anthracylines)	in	other	paediatric	cancer	survivors	(Jenkinson	et	al.,	2007,	Henderson	et	
al.,	2012)		
We	have	developed	a	small	cohort	of	RB	survivors	treated	between	1995	and	
2006	at	one	institution	to	evaluate	the	risk	associated	with	chemotherapy,	but	they	will	
have	to	be	followed	for	many	more	years	and	combined	with	other	cohorts	to	have	the	
statistical	power	to	detect	increased	risks	of	second	cancers.		This	remains	an	important	
question	to	be	answered	as	more	and	more	children	are	being	treated	with	
chemotherapy.	
Because	RB	patients	have	excellent	survival	but	face	an	increased	risk	of	sarcomas	
and	melanoma	due	to	their	germline	mutation	and	past	therapy,	it	is	important	to	
develop	survivorship	guidelines	for	these	survivors.	
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9.8	Future	efforts	
Through	this	series	of	analyses,	my	colleagues	and	I	have	followed	a	unique	
cohort	of	almost	1800	RB	survivors	treated	as	early	as	1914,	and	have	shown	the	
increased	risk	of	second	cancers	progresses	as	the	cohort	ages.	My	colleagues	and	I	at	
the	NCI	are	continuing	to	follow	these	survivors	in	order	to	describe	their	lifetime	risk	of	
second	cancers	through	surveys	and	death	certificate	notifications.		We	have	recently	
conducted	a	new	NDI	search,	have	launched	a	new	study	follow-up	using	an	on-line	
survey	to	update	information	on	cancer	incidence,	and	are	also	collecting	saliva	samples	
from	survivors	in	order	to	sequence	their	RB1	genetic	mutation.	We	expect	the	field	
effort	to	be	completed	in	Spring	2017.	
We	think	that	this	next	phase	of	study	incorporating	genotype-phenotype	
analyses	will	move	us	to	the	next	level	of	understanding	of	the	genetic	predisposition	of	
these	survivors	to	second	cancers	and	how	treatment	may	influence	this	predisposition	
on	the	molecular	level.		
An	important	next	step	would	be	the	pooling	of	epidemiologic	and	genetic	data	
from	other	large	cohorts	that	have	long-term	follow-up	in	the	UK,	the	Netherlands	and	
Germany	would	allow	further	exploration	of	the	roles	of	genetic	susceptibility	and	
treatment	to	second	cancer	risk	in	hereditary	survivors.	By	pooling	the	data,	we	would	be	
able	to	address	the	following	aims:	a)	quantify	second	cancer	risks	associated	with	
chemotherapy	(without	radiotherapy)	for	patients	treated	in	the	current	era,	b)	identify	
specific	RB1	mutations	associated	with	sarcomas	and	melanomas,	c)	identifying	other	
genetic	variants	that	are	associated	with	second	cancer	risk,	and	d)	evaluate	the	
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molecular	profile	of	second	tumors	occurring	in	RB	survivors	compared	with	sporadic	
second	tumor	cases	and	comparing	characteristics	of	irradiated	and	unirradiated	tumors.		
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Appendix	1	–	Data	collection	instruments,	newsletters	
A1.1	–	medical	record	abstract	form	
A1.2	–	telephone	questionnaire		
A1.3	–	newsletters	(2001,	2005)	
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